{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p0", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits ([E1]TFIIIC102[/E1] and [E2]TFIIIC63[/E2]) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIIC102", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "pm0125479", "entity_1_type_id": 0, "entity_2": "TFIIIC63", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "pm0100174", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p1", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits ([E1]TFIIIC102[/E1] and TFIIIC63) of human [E2]TFIIIC[/E2] and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIIC102", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "pm0125479", "entity_1_type_id": 0, "entity_2": "TFIIIC", "entity_2_idx": [[104, 110]], "entity_2_idx_in_text_with_entity_marker": [117, 123], "entity_2_type": "pm0120026", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "HPRD50.d1.s0_HPRD50.d1.s0.p0", "text": "Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2", "text_with_entity_marker": "Identification of residues in the [E1]monocyte chemotactic protein-1[/E1] that contact the MCP-1 receptor, [E2]CCR2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "monocyte chemotactic protein-1", "entity_1_idx": [[34, 64]], "entity_1_idx_in_text_with_entity_marker": [38, 68], "entity_1_type": "pm0117207", "entity_1_type_id": 3, "entity_2": "CCR2", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "pm0111607", "entity_2_type_id": 4}], "directed": false, "reverse": false}
{"id": "HPRD50.d1.s1_HPRD50.d1.s1.p0", "text": "The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity", "text_with_entity_marker": "The receptor binding site of [E1]MCP-1[/E1] also is significantly different from the binding sites of [E2]RANTES[/E2] and IL-8, providing insight into the issue of receptor specificity", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0111607||pm0117207||pm0124628", "entity_1_type_id": 5, "entity_2": "RANTES", "entity_2_idx": [[93, 99]], "entity_2_idx_in_text_with_entity_marker": [106, 112], "entity_2_type": "pm0105763", "entity_2_type_id": 6}], "directed": false, "reverse": false}
{"id": "HPRD50.d1.s1_HPRD50.d1.s1.p1", "text": "The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity", "text_with_entity_marker": "The receptor binding site of [E1]MCP-1[/E1] also is significantly different from the binding sites of RANTES and [E2]IL-8[/E2], providing insight into the issue of receptor specificity", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0111607||pm0117207||pm0124628", "entity_1_type_id": 5, "entity_2": "IL-8", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "pm0121149", "entity_2_type_id": 7}], "directed": false, "reverse": false}
{"id": "HPRD50.d1.s2_HPRD50.d1.s2.p0", "text": "It was previously shown that the N-terminus of CCR2 is critical for binding MCP-1", "text_with_entity_marker": "It was previously shown that the N-terminus of [E1]CCR2[/E1] is critical for binding [E2]MCP-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "pm0111607", "entity_1_type_id": 4, "entity_2": "MCP-1", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "pm0111607||pm0117207||pm0124628", "entity_2_type_id": 5}], "directed": false, "reverse": false}
{"id": "HPRD50.d1.s3_HPRD50.d1.s3.p0", "text": "To identify the regions of MCP-1 that contact its receptor, CCR2, we substituted all surface-exposed residues with alanine", "text_with_entity_marker": "To identify the regions of [E1]MCP-1[/E1] that contact its receptor, [E2]CCR2[/E2], we substituted all surface-exposed residues with alanine", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MCP-1", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "pm0111607||pm0117207||pm0124628", "entity_1_type_id": 5, "entity_2": "CCR2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "pm0111607", "entity_2_type_id": 4}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s0_HPRD50.d2.s0.p0", "text": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer", "text_with_entity_marker": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the [E1]CG beta[/E1] subunit or the [E2]CG beta alpha[/E2] and FSH beta monomer", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[94, 101]], "entity_1_idx_in_text_with_entity_marker": [98, 105], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "CG beta alpha", "entity_2_idx": [[117, 130]], "entity_2_idx_in_text_with_entity_marker": [130, 143], "entity_2_type": "pm0125097", "entity_2_type_id": 8}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s0_HPRD50.d2.s0.p1", "text": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer", "text_with_entity_marker": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the [E1]CG beta[/E1] subunit or the CG beta alpha and [E2]FSH beta[/E2] monomer", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[94, 101]], "entity_1_idx_in_text_with_entity_marker": [98, 105], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "FSH beta", "entity_2_idx": [[135, 143]], "entity_2_idx_in_text_with_entity_marker": [148, 156], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s0_HPRD50.d2.s0.p2", "text": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer", "text_with_entity_marker": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the [E1]CG beta alpha[/E1] and [E2]FSH beta[/E2] monomer", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta alpha", "entity_1_idx": [[117, 130]], "entity_1_idx_in_text_with_entity_marker": [121, 134], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "FSH beta", "entity_2_idx": [[135, 143]], "entity_2_idx_in_text_with_entity_marker": [148, 156], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s1_HPRD50.d2.s1.p0", "text": "The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/CG beta subunit since CG single chain interacts with the monomeric FSH beta subunit and exhibits FSH activity", "text_with_entity_marker": "The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/[E1]CG beta[/E1] subunit since CG single chain interacts with the monomeric [E2]FSH beta[/E2] subunit and exhibits FSH activity", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[102, 109]], "entity_1_idx_in_text_with_entity_marker": [106, 113], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "FSH beta", "entity_2_idx": [[169, 177]], "entity_2_idx_in_text_with_entity_marker": [182, 190], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s2_HPRD50.d2.s2.p0", "text": "This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the LH beta or FSH beta subunits are different", "text_with_entity_marker": "This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the [E1]LH beta[/E1] or [E2]FSH beta[/E2] subunits are different", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LH beta", "entity_1_idx": [[206, 213]], "entity_1_idx_in_text_with_entity_marker": [210, 217], "entity_1_type": "pm0117290", "entity_1_type_id": 10, "entity_2": "FSH beta", "entity_2_idx": [[217, 225]], "entity_2_idx_in_text_with_entity_marker": [230, 238], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s3_HPRD50.d2.s3.p0", "text": "Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively", "text_with_entity_marker": "Previously, we showed that the [E1]CG beta[/E1] or [E2]FSH beta[/E2] subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[31, 38]], "entity_1_idx_in_text_with_entity_marker": [35, 42], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "FSH beta", "entity_2_idx": [[42, 50]], "entity_2_idx_in_text_with_entity_marker": [55, 63], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s3_HPRD50.d2.s3.p1", "text": "Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively", "text_with_entity_marker": "Previously, we showed that the [E1]CG beta[/E1] or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, [E2]CG beta alpha[/E2] and F beta alpha, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[31, 38]], "entity_1_idx_in_text_with_entity_marker": [35, 42], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "CG beta alpha", "entity_2_idx": [[154, 167]], "entity_2_idx_in_text_with_entity_marker": [167, 180], "entity_2_type": "pm0125097", "entity_2_type_id": 8}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s3_HPRD50.d2.s3.p2", "text": "Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively", "text_with_entity_marker": "Previously, we showed that the CG beta or [E1]FSH beta[/E1] subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, [E2]CG beta alpha[/E2] and F beta alpha, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FSH beta", "entity_1_idx": [[42, 50]], "entity_1_idx_in_text_with_entity_marker": [46, 54], "entity_1_type": "pm0104723", "entity_1_type_id": 9, "entity_2": "CG beta alpha", "entity_2_idx": [[154, 167]], "entity_2_idx_in_text_with_entity_marker": [167, 180], "entity_2_type": "pm0125097", "entity_2_type_id": 8}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s0_HPRD50.d3.s0.p0", "text": "Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines", "text_with_entity_marker": "[E1]Interleukin-6[/E1] activates [E2]phosphatidylinositol-3 kinase[/E2], which inhibits apoptosis in human prostate cancer cell lines", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Interleukin-6", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "phosphatidylinositol-3 kinase", "entity_2_idx": [[24, 53]], "entity_2_idx_in_text_with_entity_marker": [37, 66], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s1_HPRD50.d3.s1.p0", "text": "RESULTS: Tyrosine phosphorylation of p85 is upregulated by IL-6 in both LNCaP and PC-3", "text_with_entity_marker": "RESULTS: Tyrosine phosphorylation of p85 is upregulated by [E1]IL-6[/E1] in both LNCaP and [E2]PC-3[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "PC-3", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "pm0107379||pm0107715||pm0114827", "entity_2_type_id": 13}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s2_HPRD50.d3.s2.p0", "text": "IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor", "text_with_entity_marker": "[E1]IL-6[/E1] promotes coprecipitation of p85 with [E2]gp130[/E2], the signal-transducing component of the IL-6 receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "gp130", "entity_2_idx": [[42, 47]], "entity_2_idx_in_text_with_entity_marker": [55, 60], "entity_2_type": "pm0113266||pm0122272", "entity_2_type_id": 14}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s2_HPRD50.d3.s2.p1", "text": "IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor", "text_with_entity_marker": "[E1]IL-6[/E1] promotes coprecipitation of p85 with gp130, the signal-transducing component of the [E2]IL-6 receptor[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "IL-6 receptor", "entity_2_idx": [[89, 102]], "entity_2_idx_in_text_with_entity_marker": [102, 115], "entity_2_type": "pm0106299", "entity_2_type_id": 15}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s2_HPRD50.d3.s2.p2", "text": "IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor", "text_with_entity_marker": "IL-6 promotes coprecipitation of p85 with [E1]gp130[/E1], the signal-transducing component of the [E2]IL-6 receptor[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[42, 47]], "entity_1_idx_in_text_with_entity_marker": [46, 51], "entity_1_type": "pm0113266||pm0122272", "entity_1_type_id": 14, "entity_2": "IL-6 receptor", "entity_2_idx": [[89, 102]], "entity_2_idx_in_text_with_entity_marker": [102, 115], "entity_2_type": "pm0106299", "entity_2_type_id": 15}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s0_HPRD50.d4.s0.p0", "text": "In solution, FGFR4ed formed complexes with acidic FGF (FGF-1) and basic FGF (FGF-2), both in the presence and absence of heparin", "text_with_entity_marker": "In solution, FGFR4ed formed complexes with [E1]acidic FGF (FGF-1)[/E1] and [E2]basic FGF (FGF-2)[/E2], both in the presence and absence of heparin", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "acidic FGF (FGF-1)", "entity_1_idx": [[43, 61]], "entity_1_idx_in_text_with_entity_marker": [47, 65], "entity_1_type": "pm0124654", "entity_1_type_id": 16, "entity_2": "basic FGF (FGF-2)", "entity_2_idx": [[66, 83]], "entity_2_idx_in_text_with_entity_marker": [79, 96], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p0", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized [E1]FGFR4[/E1] also bound [E2]FGF-8[/E2] besides FGF-1 and FGF-2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR4", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "pm0119069", "entity_1_type_id": 18, "entity_2": "FGF-8", "entity_2_idx": [[29, 34]], "entity_2_idx_in_text_with_entity_marker": [42, 47], "entity_2_type": "pm0118903", "entity_2_type_id": 19}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p1", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized [E1]FGFR4[/E1] also bound FGF-8 besides [E2]FGF-1[/E2] and FGF-2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR4", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "pm0119069", "entity_1_type_id": 18, "entity_2": "FGF-1", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "pm0124654", "entity_2_type_id": 16}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p2", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized [E1]FGFR4[/E1] also bound FGF-8 besides FGF-1 and [E2]FGF-2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR4", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "pm0119069", "entity_1_type_id": 18, "entity_2": "FGF-2", "entity_2_idx": [[53, 58]], "entity_2_idx_in_text_with_entity_marker": [66, 71], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p3", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized FGFR4 also bound [E1]FGF-8[/E1] besides [E2]FGF-1[/E2] and FGF-2", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-8", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0118903", "entity_1_type_id": 19, "entity_2": "FGF-1", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "pm0124654", "entity_2_type_id": 16}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p4", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized FGFR4 also bound [E1]FGF-8[/E1] besides FGF-1 and [E2]FGF-2[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-8", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0118903", "entity_1_type_id": 19, "entity_2": "FGF-2", "entity_2_idx": [[53, 58]], "entity_2_idx_in_text_with_entity_marker": [66, 71], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p5", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized FGFR4 also bound FGF-8 besides [E1]FGF-1[/E1] and [E2]FGF-2[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-1", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "pm0124654", "entity_1_type_id": 16, "entity_2": "FGF-2", "entity_2_idx": [[53, 58]], "entity_2_idx_in_text_with_entity_marker": [66, 71], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s1_HPRD50.d5.s1.p0", "text": "Here we provide evidence of how cytohesin-1, an integrin-binding protein and guanine-nucleotide exchange factor (GEF) for ARF GTPases, regulates cell adhesion", "text_with_entity_marker": "Here we provide evidence of how [E1]cytohesin-1[/E1], an integrin-binding protein and guanine-nucleotide exchange factor (GEF) for [E2]ARF[/E2] GTPases, regulates cell adhesion", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cytohesin-1", "entity_1_idx": [[32, 43]], "entity_1_idx_in_text_with_entity_marker": [36, 47], "entity_1_type": "pm0124251", "entity_1_type_id": 20, "entity_2": "ARF", "entity_2_idx": [[122, 125]], "entity_2_idx_in_text_with_entity_marker": [135, 138], "entity_2_type": "pm0126206", "entity_2_type_id": 22}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s2_HPRD50.d5.s2.p0", "text": "Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of LFA-1 depends on its interaction with cytohesin-1, unless the integrin is activated by exogenous divalent cations", "text_with_entity_marker": "Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of [E1]LFA-1[/E1] depends on its interaction with [E2]cytohesin-1[/E2], unless the integrin is activated by exogenous divalent cations", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LFA-1", "entity_1_idx": [[92, 97]], "entity_1_idx_in_text_with_entity_marker": [96, 101], "entity_1_type": "pm0104657||pm0114514", "entity_1_type_id": 21, "entity_2": "cytohesin-1", "entity_2_idx": [[130, 141]], "entity_2_idx_in_text_with_entity_marker": [143, 154], "entity_2_type": "pm0124251", "entity_2_type_id": 20}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s3_HPRD50.d5.s3.p0", "text": "Secondly, cytohesin-1 induces expression of an extracellular activation epitope of LFA-1, and the exchange factor function is not essential for this activity", "text_with_entity_marker": "Secondly, [E1]cytohesin-1[/E1] induces expression of an extracellular activation epitope of [E2]LFA-1[/E2], and the exchange factor function is not essential for this activity", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cytohesin-1", "entity_1_idx": [[10, 21]], "entity_1_idx_in_text_with_entity_marker": [14, 25], "entity_1_type": "pm0124251", "entity_1_type_id": 20, "entity_2": "LFA-1", "entity_2_idx": [[83, 88]], "entity_2_idx_in_text_with_entity_marker": [96, 101], "entity_2_type": "pm0104657||pm0114514", "entity_2_type_id": 21}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s4_HPRD50.d5.s4.p0", "text": "In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a cytohesin-1 mutant, which fails to catalyze ARF GDP-GTP exchange in vitro", "text_with_entity_marker": "In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a [E1]cytohesin-1[/E1] mutant, which fails to catalyze [E2]ARF[/E2] GDP-GTP exchange in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cytohesin-1", "entity_1_idx": [[125, 136]], "entity_1_idx_in_text_with_entity_marker": [129, 140], "entity_1_type": "pm0124251", "entity_1_type_id": 20, "entity_2": "ARF", "entity_2_idx": [[169, 172]], "entity_2_idx_in_text_with_entity_marker": [182, 185], "entity_2_type": "pm0126206", "entity_2_type_id": 22}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s0_HPRD50.d6.s0.p0", "text": "Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Jak2, p125FAK, and paxillin", "text_with_entity_marker": "Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of [E1]Jak2[/E1], p125FAK, and [E2]paxillin[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "paxillin", "entity_2_idx": [[121, 129]], "entity_2_idx_in_text_with_entity_marker": [134, 142], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s1_HPRD50.d6.s1.p0", "text": "These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of Jak2, p125FAK, and paxillin and actin polymerization", "text_with_entity_marker": "These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of [E1]Jak2[/E1], p125FAK, and [E2]paxillin[/E2] and actin polymerization", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "paxillin", "entity_2_idx": [[125, 133]], "entity_2_idx_in_text_with_entity_marker": [138, 146], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s2_HPRD50.d6.s2.p0", "text": "Pituitary GH triggered the tyrosine phosphorylation of Janus kinase 2 (Jak2) and STAT3 in neutrophils", "text_with_entity_marker": "Pituitary GH triggered the tyrosine phosphorylation of [E1]Janus kinase 2[/E1] ([E2]Jak2[/E2]) and STAT3 in neutrophils", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Janus kinase 2", "entity_1_idx": [[55, 69]], "entity_1_idx_in_text_with_entity_marker": [59, 73], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "Jak2", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "pm0110818", "entity_2_type_id": 23}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s2_HPRD50.d6.s2.p1", "text": "Pituitary GH triggered the tyrosine phosphorylation of Janus kinase 2 (Jak2) and STAT3 in neutrophils", "text_with_entity_marker": "Pituitary GH triggered the tyrosine phosphorylation of [E1]Janus kinase 2[/E1] (Jak2) and [E2]STAT3[/E2] in neutrophils", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Janus kinase 2", "entity_1_idx": [[55, 69]], "entity_1_idx_in_text_with_entity_marker": [59, 73], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "STAT3", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "pm0118656", "entity_2_type_id": 25}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s2_HPRD50.d6.s2.p2", "text": "Pituitary GH triggered the tyrosine phosphorylation of Janus kinase 2 (Jak2) and STAT3 in neutrophils", "text_with_entity_marker": "Pituitary GH triggered the tyrosine phosphorylation of Janus kinase 2 ([E1]Jak2[/E1]) and [E2]STAT3[/E2] in neutrophils", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "STAT3", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "pm0118656", "entity_2_type_id": 25}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s3_HPRD50.d6.s3.p0", "text": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, STAT3, p125FAK, and paxillin phosphorylation", "text_with_entity_marker": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and [E1]Jak2[/E1], [E2]STAT3[/E2], p125FAK, and paxillin phosphorylation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[98, 102]], "entity_1_idx_in_text_with_entity_marker": [102, 106], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "STAT3", "entity_2_idx": [[104, 109]], "entity_2_idx_in_text_with_entity_marker": [117, 122], "entity_2_type": "pm0118656", "entity_2_type_id": 25}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s3_HPRD50.d6.s3.p1", "text": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, STAT3, p125FAK, and paxillin phosphorylation", "text_with_entity_marker": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and [E1]Jak2[/E1], STAT3, p125FAK, and [E2]paxillin[/E2] phosphorylation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[98, 102]], "entity_1_idx_in_text_with_entity_marker": [102, 106], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "paxillin", "entity_2_idx": [[124, 132]], "entity_2_idx_in_text_with_entity_marker": [137, 145], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s3_HPRD50.d6.s3.p2", "text": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, STAT3, p125FAK, and paxillin phosphorylation", "text_with_entity_marker": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, [E1]STAT3[/E1], p125FAK, and [E2]paxillin[/E2] phosphorylation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "STAT3", "entity_1_idx": [[104, 109]], "entity_1_idx_in_text_with_entity_marker": [108, 113], "entity_1_type": "pm0118656", "entity_1_type_id": 25, "entity_2": "paxillin", "entity_2_idx": [[124, 132]], "entity_2_idx_in_text_with_entity_marker": [137, 145], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s0_HPRD50.d7.s0.p0", "text": "Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2", "text_with_entity_marker": "Suppression of rat thromboxane synthase gene transcription by [E1]peroxisome proliferator-activated receptor gamma[/E1] in macrophages via an interaction with [E2]NRF2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "peroxisome proliferator-activated receptor gamma", "entity_1_idx": [[62, 110]], "entity_1_idx_in_text_with_entity_marker": [66, 114], "entity_1_type": "pm0103183", "entity_1_type_id": 26, "entity_2": "NRF2", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "pm0105918||pm0123857", "entity_2_type_id": 27}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s1_HPRD50.d7.s1.p0", "text": "Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 (NF-E2)/AP-1 site (-98/-88), which was indicated to be the major promoter of the TXS gene", "text_with_entity_marker": "Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 ([E1]NF-E2[/E1])/[E2]AP-1[/E2] site (-98/-88), which was indicated to be the major promoter of the TXS gene", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-E2", "entity_1_idx": [[136, 141]], "entity_1_idx_in_text_with_entity_marker": [140, 145], "entity_1_type": "pm0120477", "entity_1_type_id": 28, "entity_2": "AP-1", "entity_2_idx": [[143, 147]], "entity_2_idx_in_text_with_entity_marker": [156, 160], "entity_2_type": "pm0103880", "entity_2_type_id": 29}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p0", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the [E1]NF-E2[/E1]/[E2]AP-1[/E2] site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-E2", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "pm0120477", "entity_1_type_id": 28, "entity_2": "AP-1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "pm0103880", "entity_2_type_id": 29}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p1", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the [E1]NF-E2[/E1]/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor [E2]NRF2[/E2] (NF-E2-related factor 2)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-E2", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "pm0120477", "entity_1_type_id": 28, "entity_2": "NRF2", "entity_2_idx": [[235, 239]], "entity_2_idx_in_text_with_entity_marker": [248, 252], "entity_2_type": "pm0105918||pm0123857", "entity_2_type_id": 27}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p2", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the [E1]NF-E2[/E1]/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 ([E2]NF-E2-related factor 2[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-E2", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "pm0120477", "entity_1_type_id": 28, "entity_2": "NF-E2-related factor 2", "entity_2_idx": [[241, 263]], "entity_2_idx_in_text_with_entity_marker": [254, 276], "entity_2_type": "pm0105918", "entity_2_type_id": 30}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p4", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the NF-E2/[E1]AP-1[/E1] site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 ([E2]NF-E2-related factor 2[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AP-1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0103880", "entity_1_type_id": 29, "entity_2": "NF-E2-related factor 2", "entity_2_idx": [[241, 263]], "entity_2_idx_in_text_with_entity_marker": [254, 276], "entity_2_type": "pm0105918", "entity_2_type_id": 30}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p5", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor [E1]NRF2[/E1] ([E2]NF-E2-related factor 2[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NRF2", "entity_1_idx": [[235, 239]], "entity_1_idx_in_text_with_entity_marker": [239, 243], "entity_1_type": "pm0105918||pm0123857", "entity_1_type_id": 27, "entity_2": "NF-E2-related factor 2", "entity_2_idx": [[241, 263]], "entity_2_idx_in_text_with_entity_marker": [254, 276], "entity_2_type": "pm0105918", "entity_2_type_id": 30}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s3_HPRD50.d7.s3.p0", "text": "Finally, a direct interaction between PPARgamma and NRF2 was confirmed by glutathione S-transferase pull-down assay", "text_with_entity_marker": "Finally, a direct interaction between PPARgamma and [E1]NRF2[/E1] was confirmed by [E2]glutathione S-transferase[/E2] pull-down assay", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NRF2", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "pm0105918||pm0123857", "entity_1_type_id": 27, "entity_2": "glutathione S-transferase", "entity_2_idx": [[74, 99]], "entity_2_idx_in_text_with_entity_marker": [87, 112], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d8.s0_HPRD50.d8.s0.p0", "text": "By constructing deletion mutants, we identified that amino acid residues 229-309 of Akt were involved in the binding to Hsp90 and amino acid residues 327-340 of Hsp90beta were involved in the binding to Akt", "text_with_entity_marker": "By constructing deletion mutants, we identified that amino acid residues 229-309 of Akt were involved in the binding to [E1]Hsp90[/E1] and amino acid residues 327-340 of [E2]Hsp90beta[/E2] were involved in the binding to Akt", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hsp90", "entity_1_idx": [[120, 125]], "entity_1_idx_in_text_with_entity_marker": [124, 129], "entity_1_type": "pm0114253||pm0121838", "entity_1_type_id": 32, "entity_2": "Hsp90beta", "entity_2_idx": [[161, 170]], "entity_2_idx_in_text_with_entity_marker": [174, 183], "entity_2_type": "pm0121838", "entity_2_type_id": 33}], "directed": false, "reverse": false}
{"id": "HPRD50.d9.s0_HPRD50.d9.s0.p0", "text": "Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)", "text_with_entity_marker": "Here, we cloned and characterized a mouse orthologue of human [E1]KIAA1427[/E1] protein as an atypical [E2]Syt[/E2] (named Syt XIII)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KIAA1427", "entity_1_idx": [[62, 70]], "entity_1_idx_in_text_with_entity_marker": [66, 74], "entity_1_type": "pm0110335", "entity_1_type_id": 34, "entity_2": "Syt", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "pm0109470||pm0116152", "entity_2_type_id": 35}], "directed": false, "reverse": false}
{"id": "HPRD50.d9.s0_HPRD50.d9.s0.p2", "text": "Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)", "text_with_entity_marker": "Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical [E1]Syt[/E1] (named [E2]Syt XIII[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syt", "entity_1_idx": [[94, 97]], "entity_1_idx_in_text_with_entity_marker": [98, 101], "entity_1_type": "pm0109470||pm0116152", "entity_1_type_id": 35, "entity_2": "Syt XIII", "entity_2_idx": [[105, 113]], "entity_2_idx_in_text_with_entity_marker": [118, 126], "entity_2_type": "pm0110335", "entity_2_type_id": 34}], "directed": false, "reverse": false}
{"id": "HPRD50.d9.s1_HPRD50.d9.s1.p0", "text": "Subcellular fractionation and antibody-uptake experiments indicate that Syt XIII is indeed a type-I membrane protein, but, unlike other Syt isoforms, lacks an N-terminal extracellular domain", "text_with_entity_marker": "Subcellular fractionation and antibody-uptake experiments indicate that [E1]Syt XIII[/E1] is indeed a type-I membrane protein, but, unlike other [E2]Syt[/E2] isoforms, lacks an N-terminal extracellular domain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syt XIII", "entity_1_idx": [[72, 80]], "entity_1_idx_in_text_with_entity_marker": [76, 84], "entity_1_type": "pm0110335", "entity_1_type_id": 34, "entity_2": "Syt", "entity_2_idx": [[136, 139]], "entity_2_idx_in_text_with_entity_marker": [149, 152], "entity_2_type": "pm0109470||pm0116152", "entity_2_type_id": 35}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s0_HPRD50.d10.s0.p0", "text": "Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1)", "text_with_entity_marker": "Cutting edge: [E1]CD43[/E1] functions as a T cell counterreceptor for the macrophage adhesion receptor [E2]sialoadhesin[/E2] (Siglec-1)", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD43", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "sialoadhesin", "entity_2_idx": [[94, 106]], "entity_2_idx_in_text_with_entity_marker": [107, 119], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s0_HPRD50.d10.s0.p1", "text": "Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1)", "text_with_entity_marker": "Cutting edge: [E1]CD43[/E1] functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin ([E2]Siglec-1[/E2])", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD43", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "Siglec-1", "entity_2_idx": [[108, 116]], "entity_2_idx_in_text_with_entity_marker": [121, 129], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s0_HPRD50.d10.s0.p2", "text": "Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1)", "text_with_entity_marker": "Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor [E1]sialoadhesin[/E1] ([E2]Siglec-1[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sialoadhesin", "entity_1_idx": [[94, 106]], "entity_1_idx_in_text_with_entity_marker": [98, 110], "entity_1_type": "pm0108007", "entity_1_type_id": 37, "entity_2": "Siglec-1", "entity_2_idx": [[108, 116]], "entity_2_idx_in_text_with_entity_marker": [121, 129], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s1_HPRD50.d10.s1.p1", "text": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins CD43 and P-selectin glycoprotein ligand 1 (CD162), respectively", "text_with_entity_marker": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins [E1]CD43[/E1] and P-selectin glycoprotein ligand 1 ([E2]CD162[/E2]), respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD43", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [95, 99], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "CD162", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "pm0119091", "entity_2_type_id": 38}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s1_HPRD50.d10.s1.p2", "text": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins CD43 and P-selectin glycoprotein ligand 1 (CD162), respectively", "text_with_entity_marker": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins CD43 and [E1]P-selectin glycoprotein ligand 1[/E1] ([E2]CD162[/E2]), respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "P-selectin glycoprotein ligand 1", "entity_1_idx": [[100, 132]], "entity_1_idx_in_text_with_entity_marker": [104, 136], "entity_1_type": "pm0119091", "entity_1_type_id": 38, "entity_2": "CD162", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "pm0119091", "entity_2_type_id": 38}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s2_HPRD50.d10.s2.p0", "text": "CD43 expressed in COS cells supported increased binding to immobilized sialoadhesin", "text_with_entity_marker": "[E1]CD43[/E1] expressed in COS cells supported increased binding to immobilized [E2]sialoadhesin[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD43", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "sialoadhesin", "entity_2_idx": [[71, 83]], "entity_2_idx_in_text_with_entity_marker": [84, 96], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s3_HPRD50.d10.s3.p0", "text": "Finally, sialoadhesin bound different glycoforms of CD43 expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on CD43 in resting and activated T cells, respectively", "text_with_entity_marker": "Finally, [E1]sialoadhesin[/E1] bound different glycoforms of [E2]CD43[/E2] expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on CD43 in resting and activated T cells, respectively", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "sialoadhesin", "entity_1_idx": [[9, 21]], "entity_1_idx_in_text_with_entity_marker": [13, 25], "entity_1_type": "pm0108007", "entity_1_type_id": 37, "entity_2": "CD43", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s3_HPRD50.d10.s3.p2", "text": "Finally, sialoadhesin bound different glycoforms of CD43 expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on CD43 in resting and activated T cells, respectively", "text_with_entity_marker": "Finally, sialoadhesin bound different glycoforms of [E1]CD43[/E1] expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on [E2]CD43[/E2] in resting and activated T cells, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD43", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "CD43", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s4_HPRD50.d10.s4.p0", "text": "These results identify CD43 as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "text_with_entity_marker": "These results identify [E1]CD43[/E1] as a T cell counterreceptor for [E2]sialoadhesin[/E2] and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD43", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "sialoadhesin", "entity_2_idx": [[60, 72]], "entity_2_idx_in_text_with_entity_marker": [73, 85], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s4_HPRD50.d10.s4.p1", "text": "These results identify CD43 as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "text_with_entity_marker": "These results identify [E1]CD43[/E1] as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role [E2]CD43[/E2] may promote cell-cell interactions", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD43", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "CD43", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s4_HPRD50.d10.s4.p2", "text": "These results identify CD43 as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "text_with_entity_marker": "These results identify CD43 as a T cell counterreceptor for [E1]sialoadhesin[/E1] and suggest that in addition to its anti-adhesive role [E2]CD43[/E2] may promote cell-cell interactions", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sialoadhesin", "entity_1_idx": [[60, 72]], "entity_1_idx_in_text_with_entity_marker": [64, 76], "entity_1_type": "pm0108007", "entity_1_type_id": 37, "entity_2": "CD43", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d11.s0_HPRD50.d11.s0.p0", "text": "Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells", "text_with_entity_marker": "Direct interaction between the cytoplasmic tail of [E1]ADAM 12[/E1] and the Src homology 3 domain of [E2]p85alpha[/E2] activates phosphatidylinositol 3-kinase in C2C12 cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ADAM 12", "entity_1_idx": [[51, 58]], "entity_1_idx_in_text_with_entity_marker": [55, 62], "entity_1_type": "pm0118647", "entity_1_type_id": 39, "entity_2": "p85alpha", "entity_2_idx": [[92, 100]], "entity_2_idx_in_text_with_entity_marker": [105, 113], "entity_2_type": "pm0124741", "entity_2_type_id": 40}], "directed": false, "reverse": false}
{"id": "HPRD50.d11.s0_HPRD50.d11.s0.p1", "text": "Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells", "text_with_entity_marker": "Direct interaction between the cytoplasmic tail of [E1]ADAM 12[/E1] and the Src homology 3 domain of p85alpha activates [E2]phosphatidylinositol 3-kinase[/E2] in C2C12 cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ADAM 12", "entity_1_idx": [[51, 58]], "entity_1_idx_in_text_with_entity_marker": [55, 62], "entity_1_type": "pm0118647", "entity_1_type_id": 39, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[111, 140]], "entity_2_idx_in_text_with_entity_marker": [124, 153], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d11.s0_HPRD50.d11.s0.p2", "text": "Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells", "text_with_entity_marker": "Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of [E1]p85alpha[/E1] activates [E2]phosphatidylinositol 3-kinase[/E2] in C2C12 cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85alpha", "entity_1_idx": [[92, 100]], "entity_1_idx_in_text_with_entity_marker": [96, 104], "entity_1_type": "pm0124741", "entity_1_type_id": 40, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[111, 140]], "entity_2_idx_in_text_with_entity_marker": [124, 153], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d11.s1_HPRD50.d11.s1.p0", "text": "This suggests that transmembrane ADAM 12, by providing docking sites for the Src homology 3 domain of p85alpha, activates PI 3-kinase by mediating its recruitment to the membrane", "text_with_entity_marker": "This suggests that transmembrane [E1]ADAM 12[/E1], by providing docking sites for the Src homology 3 domain of [E2]p85alpha[/E2], activates PI 3-kinase by mediating its recruitment to the membrane", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ADAM 12", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0118647", "entity_1_type_id": 39, "entity_2": "p85alpha", "entity_2_idx": [[102, 110]], "entity_2_idx_in_text_with_entity_marker": [115, 123], "entity_2_type": "pm0124741", "entity_2_type_id": 40}], "directed": false, "reverse": false}
{"id": "HPRD50.d12.s0_HPRD50.d12.s0.p0", "text": "AP180 binds to the C-terminal SH2 domain of phospholipase C-gamma1 and inhibits its enzymatic activity", "text_with_entity_marker": "[E1]AP180[/E1] binds to the C-terminal SH2 domain of [E2]phospholipase C-gamma1[/E2] and inhibits its enzymatic activity", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "AP180", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0106306", "entity_1_type_id": 41, "entity_2": "phospholipase C-gamma1", "entity_2_idx": [[44, 66]], "entity_2_idx_in_text_with_entity_marker": [57, 79], "entity_2_type": "pm0126499", "entity_2_type_id": 42}], "directed": false, "reverse": false}
{"id": "HPRD50.d12.s1_HPRD50.d12.s1.p0", "text": "In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner", "text_with_entity_marker": "In this report, we demonstrate the stable association of [E1]PLCgamma1[/E1] with [E2]AP180[/E2] in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PLCgamma1", "entity_1_idx": [[57, 66]], "entity_1_idx_in_text_with_entity_marker": [61, 70], "entity_1_type": "pm0126499", "entity_1_type_id": 42, "entity_2": "AP180", "entity_2_idx": [[72, 77]], "entity_2_idx_in_text_with_entity_marker": [85, 90], "entity_2_type": "pm0106306", "entity_2_type_id": 41}], "directed": false, "reverse": false}
{"id": "HPRD50.d12.s1_HPRD50.d12.s1.p2", "text": "In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner", "text_with_entity_marker": "In this report, we demonstrate the stable association of PLCgamma1 with [E1]AP180[/E1] in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of [E2]PLCgamma1[/E2], but also inhibits its enzymatic activity in a dose-dependent manner", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "AP180", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "pm0106306", "entity_1_type_id": 41, "entity_2": "PLCgamma1", "entity_2_idx": [[176, 185]], "entity_2_idx_in_text_with_entity_marker": [189, 198], "entity_2_type": "pm0126499", "entity_2_type_id": 42}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s0_HPRD50.d13.s0.p0", "text": "Here we demonstrate colocalization and direct interaction between CLIP-170 and LIS1", "text_with_entity_marker": "Here we demonstrate colocalization and direct interaction between [E1]CLIP-170[/E1] and [E2]LIS1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CLIP-170", "entity_1_idx": [[66, 74]], "entity_1_idx_in_text_with_entity_marker": [70, 78], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "LIS1", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p0", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of [E1]CLIP-170[/E1] results in a zinc finger-dependent localization of a [E2]phospho-LIS1[/E2] isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CLIP-170", "entity_1_idx": [[18, 26]], "entity_1_idx_in_text_with_entity_marker": [22, 30], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "phospho-LIS1", "entity_2_idx": [[80, 92]], "entity_2_idx_in_text_with_entity_marker": [93, 105], "entity_2_type": "phospho-pm0110467", "entity_2_type_id": 45}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p1", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of [E1]CLIP-170[/E1] results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that [E2]CLIP-170[/E2] and LIS1 regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CLIP-170", "entity_1_idx": [[18, 26]], "entity_1_idx_in_text_with_entity_marker": [22, 30], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "CLIP-170", "entity_2_idx": [[158, 166]], "entity_2_idx_in_text_with_entity_marker": [171, 179], "entity_2_type": "pm0124985", "entity_2_type_id": 43}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p2", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of [E1]CLIP-170[/E1] results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and [E2]LIS1[/E2] regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CLIP-170", "entity_1_idx": [[18, 26]], "entity_1_idx_in_text_with_entity_marker": [22, 30], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "LIS1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p4", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a [E1]phospho-LIS1[/E1] isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and [E2]LIS1[/E2] regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phospho-LIS1", "entity_1_idx": [[80, 92]], "entity_1_idx_in_text_with_entity_marker": [84, 96], "entity_1_type": "phospho-pm0110467", "entity_1_type_id": 45, "entity_2": "LIS1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p5", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that [E1]CLIP-170[/E1] and [E2]LIS1[/E2] regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CLIP-170", "entity_1_idx": [[158, 166]], "entity_1_idx_in_text_with_entity_marker": [162, 170], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "LIS1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s2_HPRD50.d13.s2.p0", "text": "This work suggests that LIS1 is a regulated adapter between CLIP-170 and cytoplasmic dynein at sites involved in cargo-MT loading, and/or in the control of MT dynamics", "text_with_entity_marker": "This work suggests that [E1]LIS1[/E1] is a regulated adapter between [E2]CLIP-170[/E2] and cytoplasmic dynein at sites involved in cargo-MT loading, and/or in the control of MT dynamics", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LIS1", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "pm0110467", "entity_1_type_id": 44, "entity_2": "CLIP-170", "entity_2_idx": [[60, 68]], "entity_2_idx_in_text_with_entity_marker": [73, 81], "entity_2_type": "pm0124985", "entity_2_type_id": 43}], "directed": false, "reverse": false}
{"id": "HPRD50.d14.s1_HPRD50.d14.s1.p0", "text": "Megalin and cubilin are two structurally different endocytic receptors that interact to serve such functions", "text_with_entity_marker": "[E1]Megalin[/E1] and [E2]cubilin[/E2] are two structurally different endocytic receptors that interact to serve such functions", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Megalin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0100604", "entity_1_type_id": 46, "entity_2": "cubilin", "entity_2_idx": [[12, 19]], "entity_2_idx_in_text_with_entity_marker": [25, 32], "entity_2_type": "pm0100963", "entity_2_type_id": 47}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s0_HPRD50.d15.s0.p0", "text": "Physical association of beta 2 integrin with GPI-80, a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration", "text_with_entity_marker": "Physical association of [E1]beta 2 integrin[/E1] with [E2]GPI-80[/E2], a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "beta 2 integrin", "entity_1_idx": [[24, 39]], "entity_1_idx_in_text_with_entity_marker": [28, 43], "entity_1_type": "pm0114514", "entity_1_type_id": 48, "entity_2": "GPI-80", "entity_2_idx": [[45, 51]], "entity_2_idx_in_text_with_entity_marker": [58, 64], "entity_2_type": "pm0100260", "entity_2_type_id": 49}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s1_HPRD50.d15.s1.p0", "text": "To clarify the mechanisms by which GPI-80 functions on leukocytes, we explored the possibility of its physical association with beta 2 integrin which is important for leukocyte adherence, locomotion, and extravasation", "text_with_entity_marker": "To clarify the mechanisms by which [E1]GPI-80[/E1] functions on leukocytes, we explored the possibility of its physical association with [E2]beta 2 integrin[/E2] which is important for leukocyte adherence, locomotion, and extravasation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GPI-80", "entity_1_idx": [[35, 41]], "entity_1_idx_in_text_with_entity_marker": [39, 45], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "beta 2 integrin", "entity_2_idx": [[128, 143]], "entity_2_idx_in_text_with_entity_marker": [141, 156], "entity_2_type": "pm0114514", "entity_2_type_id": 48}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s2_HPRD50.d15.s2.p0", "text": "beta 2 integrin, detected by anti-CD18 mAb, was coprecipitated with GPI-80 from human neutrophil lysates by a mAb to GPI-80", "text_with_entity_marker": "[E1]beta 2 integrin[/E1], detected by anti-CD18 mAb, was coprecipitated with [E2]GPI-80[/E2] from human neutrophil lysates by a mAb to GPI-80", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "beta 2 integrin", "entity_1_idx": [[0, 15]], "entity_1_idx_in_text_with_entity_marker": [4, 19], "entity_1_type": "pm0114514", "entity_1_type_id": 48, "entity_2": "GPI-80", "entity_2_idx": [[68, 74]], "entity_2_idx_in_text_with_entity_marker": [81, 87], "entity_2_type": "pm0100260", "entity_2_type_id": 49}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s2_HPRD50.d15.s2.p1", "text": "beta 2 integrin, detected by anti-CD18 mAb, was coprecipitated with GPI-80 from human neutrophil lysates by a mAb to GPI-80", "text_with_entity_marker": "[E1]beta 2 integrin[/E1], detected by anti-CD18 mAb, was coprecipitated with GPI-80 from human neutrophil lysates by a mAb to [E2]GPI-80[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta 2 integrin", "entity_1_idx": [[0, 15]], "entity_1_idx_in_text_with_entity_marker": [4, 19], "entity_1_type": "pm0114514", "entity_1_type_id": 48, "entity_2": "GPI-80", "entity_2_idx": [[117, 123]], "entity_2_idx_in_text_with_entity_marker": [130, 136], "entity_2_type": "pm0100260", "entity_2_type_id": 49}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s2_HPRD50.d15.s2.p2", "text": "beta 2 integrin, detected by anti-CD18 mAb, was coprecipitated with GPI-80 from human neutrophil lysates by a mAb to GPI-80", "text_with_entity_marker": "beta 2 integrin, detected by anti-CD18 mAb, was coprecipitated with [E1]GPI-80[/E1] from human neutrophil lysates by a mAb to [E2]GPI-80[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GPI-80", "entity_1_idx": [[68, 74]], "entity_1_idx_in_text_with_entity_marker": [72, 78], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "GPI-80", "entity_2_idx": [[117, 123]], "entity_2_idx_in_text_with_entity_marker": [130, 136], "entity_2_type": "pm0100260", "entity_2_type_id": 49}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s3_HPRD50.d15.s3.p0", "text": "In addition, GPI-80 was immunoprecipitated from human neutrophil lysates by anti-human CD18 mAb", "text_with_entity_marker": "In addition, [E1]GPI-80[/E1] was immunoprecipitated from human neutrophil lysates by anti-human [E2]CD18[/E2] mAb", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GPI-80", "entity_1_idx": [[13, 19]], "entity_1_idx_in_text_with_entity_marker": [17, 23], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "CD18", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "pm0105418||pm0114514", "entity_2_type_id": 50}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s4_HPRD50.d15.s4.p0", "text": "These results clearly show that GPI-80 is physically associated with beta 2 integrin in human neutrophils", "text_with_entity_marker": "These results clearly show that [E1]GPI-80[/E1] is physically associated with [E2]beta 2 integrin[/E2] in human neutrophils", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GPI-80", "entity_1_idx": [[32, 38]], "entity_1_idx_in_text_with_entity_marker": [36, 42], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "beta 2 integrin", "entity_2_idx": [[69, 84]], "entity_2_idx_in_text_with_entity_marker": [82, 97], "entity_2_type": "pm0114514", "entity_2_type_id": 48}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s0_HPRD50.d16.s0.p0", "text": "GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "text_with_entity_marker": "[E1]GADD45b[/E1] and [E2]GADD45g[/E2] are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GADD45b", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "GADD45g", "entity_2_idx": [[12, 19]], "entity_2_idx_in_text_with_entity_marker": [25, 32], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s0_HPRD50.d16.s0.p1", "text": "GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "text_with_entity_marker": "[E1]GADD45b[/E1] and GADD45g are [E2]cdc2[/E2]/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45b", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "cdc2", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s0_HPRD50.d16.s0.p2", "text": "GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "text_with_entity_marker": "GADD45b and [E1]GADD45g[/E1] are [E2]cdc2[/E2]/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45g", "entity_1_idx": [[12, 19]], "entity_1_idx_in_text_with_entity_marker": [16, 23], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "cdc2", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p0", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "[E1]Gadd45a[/E1] ([E2]Gadd45[/E2]), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45", "entity_2_idx": [[9, 15]], "entity_2_idx_in_text_with_entity_marker": [22, 28], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p1", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "[E1]Gadd45a[/E1] (Gadd45), [E2]Gadd45b[/E2] (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45b", "entity_2_idx": [[18, 25]], "entity_2_idx_in_text_with_entity_marker": [31, 38], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p2", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "[E1]Gadd45a[/E1] (Gadd45), Gadd45b ([E2]MyD118[/E2]), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "MyD118", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p4", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "[E1]Gadd45a[/E1] (Gadd45), Gadd45b (MyD118), and Gadd45g ([E2]CR6[/E2]) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "CR6", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "pm0102392||pm0116690", "entity_2_type_id": 55}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p6", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a ([E1]Gadd45[/E1]), Gadd45b ([E2]MyD118[/E2]), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "MyD118", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p7", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a ([E1]Gadd45[/E1]), Gadd45b (MyD118), and [E2]Gadd45g[/E2] (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45g", "entity_2_idx": [[40, 47]], "entity_2_idx_in_text_with_entity_marker": [53, 60], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p8", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a ([E1]Gadd45[/E1]), Gadd45b (MyD118), and Gadd45g ([E2]CR6[/E2]) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "CR6", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "pm0102392||pm0116690", "entity_2_type_id": 55}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p9", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), [E1]Gadd45b[/E1] ([E2]MyD118[/E2]), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[18, 25]], "entity_1_idx_in_text_with_entity_marker": [22, 29], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "MyD118", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p10", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), [E1]Gadd45b[/E1] (MyD118), and [E2]Gadd45g[/E2] (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[18, 25]], "entity_1_idx_in_text_with_entity_marker": [22, 29], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[40, 47]], "entity_2_idx_in_text_with_entity_marker": [53, 60], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p11", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), [E1]Gadd45b[/E1] (MyD118), and Gadd45g ([E2]CR6[/E2]) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[18, 25]], "entity_1_idx_in_text_with_entity_marker": [22, 29], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "CR6", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "pm0102392||pm0116690", "entity_2_type_id": 55}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p12", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), Gadd45b ([E1]MyD118[/E1]), and [E2]Gadd45g[/E2] (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyD118", "entity_1_idx": [[27, 33]], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[40, 47]], "entity_2_idx_in_text_with_entity_marker": [53, 60], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p13", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), Gadd45b ([E1]MyD118[/E1]), and Gadd45g ([E2]CR6[/E2]) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyD118", "entity_1_idx": [[27, 33]], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "CR6", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "pm0102392||pm0116690", "entity_2_type_id": 55}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s2_HPRD50.d16.s2.p0", "text": "Recent evidence has implicated Gadd45a in inhibition of cdc2/cyclinB1 kinase and in G2/M cell cycle arrest", "text_with_entity_marker": "Recent evidence has implicated [E1]Gadd45a[/E1] in inhibition of [E2]cdc2[/E2]/cyclinB1 kinase and in G2/M cell cycle arrest", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45a", "entity_1_idx": [[31, 38]], "entity_1_idx_in_text_with_entity_marker": [35, 42], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "cdc2", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s3_HPRD50.d16.s3.p0", "text": "Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "text_with_entity_marker": "Yet, whether [E1]Gadd45b[/E1] and/or [E2]Gadd45g[/E2] function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[13, 20]], "entity_1_idx_in_text_with_entity_marker": [17, 24], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[28, 35]], "entity_2_idx_in_text_with_entity_marker": [41, 48], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s3_HPRD50.d16.s3.p1", "text": "Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "text_with_entity_marker": "Yet, whether [E1]Gadd45b[/E1] and/or Gadd45g function as inhibitors of [E2]cdc2[/E2]/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[13, 20]], "entity_1_idx_in_text_with_entity_marker": [17, 24], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "cdc2", "entity_2_idx": [[62, 66]], "entity_2_idx_in_text_with_entity_marker": [75, 79], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s3_HPRD50.d16.s3.p2", "text": "Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "text_with_entity_marker": "Yet, whether Gadd45b and/or [E1]Gadd45g[/E1] function as inhibitors of [E2]cdc2[/E2]/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45g", "entity_1_idx": [[28, 35]], "entity_1_idx_in_text_with_entity_marker": [32, 39], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "cdc2", "entity_2_idx": [[62, 66]], "entity_2_idx_in_text_with_entity_marker": [75, 79], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s4_HPRD50.d16.s4.p0", "text": "In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "text_with_entity_marker": "In this work, we show that [E1]Gadd45b[/E1] and [E2]Gadd45g[/E2] specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[39, 46]], "entity_2_idx_in_text_with_entity_marker": [52, 59], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s4_HPRD50.d16.s4.p1", "text": "In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "text_with_entity_marker": "In this work, we show that [E1]Gadd45b[/E1] and Gadd45g specifically interact with the [E2]Cdk1[/E2]/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Cdk1", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p0", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and [E2]Gadd45g[/E2], as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[45, 52]], "entity_2_idx_in_text_with_entity_marker": [58, 65], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p1", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and Gadd45g, as well as [E2]GADD45a[/E2], interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "GADD45a", "entity_2_idx": [[65, 72]], "entity_2_idx_in_text_with_entity_marker": [78, 85], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p2", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and Gadd45g, as well as GADD45a, interact with both [E2]Cdk1[/E2] and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Cdk1", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p3", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p5", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and [E1]Gadd45g[/E1], as well as GADD45a, interact with both [E2]Cdk1[/E2] and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45g", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "Cdk1", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p6", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and [E1]Gadd45g[/E1], as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45g", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p7", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and Gadd45g, as well as [E1]GADD45a[/E1], interact with both [E2]Cdk1[/E2] and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45a", "entity_1_idx": [[65, 72]], "entity_1_idx_in_text_with_entity_marker": [69, 76], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Cdk1", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p8", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and Gadd45g, as well as [E1]GADD45a[/E1], interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45a", "entity_1_idx": [[65, 72]], "entity_1_idx_in_text_with_entity_marker": [69, 76], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p9", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both [E1]Cdk1[/E1] and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk1", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p0", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of [E1]Cdk1[/E1]/cyclinB1 kinase activity by [E2]Gadd45b[/E2] and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdk1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Gadd45b", "entity_2_idx": [[47, 54]], "entity_2_idx_in_text_with_entity_marker": [60, 67], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p1", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of [E1]Cdk1[/E1]/cyclinB1 kinase activity by Gadd45b and [E2]Gadd45a[/E2] was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdk1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Gadd45a", "entity_2_idx": [[59, 66]], "entity_2_idx_in_text_with_entity_marker": [72, 79], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p2", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of [E1]Cdk1[/E1]/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas [E2]Gadd45g[/E2] did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Gadd45g", "entity_2_idx": [[123, 130]], "entity_2_idx_in_text_with_entity_marker": [136, 143], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p3", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of Cdk1/cyclinB1 kinase activity by [E1]Gadd45b[/E1] and [E2]Gadd45a[/E2] was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45a", "entity_2_idx": [[59, 66]], "entity_2_idx_in_text_with_entity_marker": [72, 79], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p4", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of Cdk1/cyclinB1 kinase activity by [E1]Gadd45b[/E1] and Gadd45a was found to involve disruption of the complex, whereas [E2]Gadd45g[/E2] did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[123, 130]], "entity_2_idx_in_text_with_entity_marker": [136, 143], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p5", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and [E1]Gadd45a[/E1] was found to involve disruption of the complex, whereas [E2]Gadd45g[/E2] did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[59, 66]], "entity_1_idx_in_text_with_entity_marker": [63, 70], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45g", "entity_2_idx": [[123, 130]], "entity_2_idx_in_text_with_entity_marker": [136, 143], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s0_HPRD50.d18.s0.p0", "text": "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)", "text_with_entity_marker": "The transmembrane [E1]receptor protein tyrosine phosphatase[/E1] [E2]DEP1[/E2] interacts with p120(ctn)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "receptor protein tyrosine phosphatase", "entity_1_idx": [[18, 55]], "entity_1_idx_in_text_with_entity_marker": [22, 59], "entity_1_type": "pm0104157", "entity_1_type_id": 58, "entity_2": "DEP1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s0_HPRD50.d18.s0.p1", "text": "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)", "text_with_entity_marker": "The transmembrane [E1]receptor protein tyrosine phosphatase[/E1] DEP1 interacts with [E2]p120(ctn)[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "receptor protein tyrosine phosphatase", "entity_1_idx": [[18, 55]], "entity_1_idx_in_text_with_entity_marker": [22, 59], "entity_1_type": "pm0104157", "entity_1_type_id": 58, "entity_2": "p120(ctn)", "entity_2_idx": [[76, 85]], "entity_2_idx_in_text_with_entity_marker": [89, 98], "entity_2_type": "pm0101886", "entity_2_type_id": 60}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s0_HPRD50.d18.s0.p2", "text": "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)", "text_with_entity_marker": "The transmembrane receptor protein tyrosine phosphatase [E1]DEP1[/E1] interacts with [E2]p120(ctn)[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DEP1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0115917", "entity_1_type_id": 59, "entity_2": "p120(ctn)", "entity_2_idx": [[76, 85]], "entity_2_idx_in_text_with_entity_marker": [89, 98], "entity_2_type": "pm0101886", "entity_2_type_id": 60}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s1_HPRD50.d18.s1.p0", "text": "The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "text_with_entity_marker": "The [E1]receptor-like protein tyrosine phosphatase[/E1] [E2]DEP1[/E2], also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "receptor-like protein tyrosine phosphatase", "entity_1_idx": [[4, 46]], "entity_1_idx_in_text_with_entity_marker": [8, 50], "entity_1_type": "pm0104157", "entity_1_type_id": 58, "entity_2": "DEP1", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s1_HPRD50.d18.s1.p2", "text": "The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "text_with_entity_marker": "The receptor-like protein tyrosine phosphatase [E1]DEP1[/E1], also known as [E2]CD148[/E2], is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "DEP1", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "pm0115917", "entity_1_type_id": 59, "entity_2": "CD148", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s3_HPRD50.d18.s3.p0", "text": "The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression", "text_with_entity_marker": "The interaction with [E1]p120(ctn)[/E1] is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and [E2]E-cadherin[/E2] expression", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p120(ctn)", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "pm0101886", "entity_1_type_id": 60, "entity_2": "E-cadherin", "entity_2_idx": [[137, 147]], "entity_2_idx_in_text_with_entity_marker": [150, 160], "entity_2_type": "pm0115783", "entity_2_type_id": 62}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s4_HPRD50.d18.s4.p1", "text": "Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific", "text_with_entity_marker": "Catalytic domains of the tyrosine phosphatases [E1]PTP-PEST[/E1], CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of [E2]DEP1[/E2] with these proteins is specific", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTP-PEST", "entity_1_idx": [[47, 55]], "entity_1_idx_in_text_with_entity_marker": [51, 59], "entity_1_type": "pm0117107", "entity_1_type_id": 63, "entity_2": "DEP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s4_HPRD50.d18.s4.p2", "text": "Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific", "text_with_entity_marker": "Catalytic domains of the tyrosine phosphatases PTP-PEST, [E1]CD45[/E1], and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of [E2]DEP1[/E2] with these proteins is specific", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD45", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "pm0110536", "entity_1_type_id": 64, "entity_2": "DEP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p0", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "[E1]p300[/E1]/[E2]cAMP-response-element-binding-protein[/E2] ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "cAMP-response-element-binding-protein", "entity_2_idx": [[5, 42]], "entity_2_idx_in_text_with_entity_marker": [18, 55], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p2", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "[E1]p300[/E1]/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A ([E2]MEF2A[/E2]) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "MEF2A", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p3", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "p300/[E1]cAMP-response-element-binding-protein[/E1] ('[E2]CREB[/E2]')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cAMP-response-element-binding-protein", "entity_1_idx": [[5, 42]], "entity_1_idx_in_text_with_entity_marker": [9, 46], "entity_1_type": "pm0100874", "entity_1_type_id": 66, "entity_2": "CREB", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p4", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "p300/[E1]cAMP-response-element-binding-protein[/E1] ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A ([E2]MEF2A[/E2]) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cAMP-response-element-binding-protein", "entity_1_idx": [[5, 42]], "entity_1_idx_in_text_with_entity_marker": [9, 46], "entity_1_type": "pm0100874", "entity_1_type_id": 66, "entity_2": "MEF2A", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p5", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "p300/cAMP-response-element-binding-protein ('[E1]CREB[/E1]')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A ([E2]MEF2A[/E2]) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CREB", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "pm0100874", "entity_1_type_id": 66, "entity_2": "MEF2A", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s1_HPRD50.d19.s1.p0", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "text_with_entity_marker": "[E1]p300[/E1]/[E2]cAMP-response-element-binding-protein[/E2] ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "cAMP-response-element-binding-protein", "entity_2_idx": [[5, 42]], "entity_2_idx_in_text_with_entity_marker": [18, 55], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s1_HPRD50.d19.s1.p1", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "text_with_entity_marker": "[E1]p300[/E1]/cAMP-response-element-binding-protein ('[E2]CREB[/E2]')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "CREB", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s1_HPRD50.d19.s1.p2", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "text_with_entity_marker": "p300/[E1]cAMP-response-element-binding-protein[/E1] ('[E2]CREB[/E2]')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cAMP-response-element-binding-protein", "entity_1_idx": [[5, 42]], "entity_1_idx_in_text_with_entity_marker": [9, 46], "entity_1_type": "pm0100874", "entity_1_type_id": 66, "entity_2": "CREB", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p0", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of [E1]p300[/E1] binds the N-terminal domains of both TR and [E2]MEF2A[/E2], and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p300", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "MEF2A", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p1", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of [E1]p300[/E1] binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, [E2]MEF2A[/E2] and p300 form a ternary complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "MEF2A", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p2", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of [E1]p300[/E1] binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and [E2]p300[/E2] form a ternary complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "p300", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0126787", "entity_2_type_id": 65}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p3", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and [E1]MEF2A[/E1], and our in vivo studies demonstrated that TR, [E2]MEF2A[/E2] and p300 form a ternary complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MEF2A", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "pm0122391", "entity_1_type_id": 67, "entity_2": "MEF2A", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p4", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and [E1]MEF2A[/E1], and our in vivo studies demonstrated that TR, MEF2A and [E2]p300[/E2] form a ternary complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MEF2A", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "pm0122391", "entity_1_type_id": 67, "entity_2": "p300", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0126787", "entity_2_type_id": 65}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p5", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, [E1]MEF2A[/E1] and [E2]p300[/E2] form a ternary complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MEF2A", "entity_1_idx": [[158, 163]], "entity_1_idx_in_text_with_entity_marker": [162, 167], "entity_1_type": "pm0122391", "entity_1_type_id": 67, "entity_2": "p300", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0126787", "entity_2_type_id": 65}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s0_HPRD50.d20.s0.p0", "text": "The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The human [E1]Imp3[/E1] and [E2]Imp4[/E2] proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp3", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp4", "entity_2_idx": [[19, 23]], "entity_2_idx_in_text_with_entity_marker": [32, 36], "entity_2_type": "pm0104160||pm0117832", "entity_2_type_id": 69}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s0_HPRD50.d20.s0.p1", "text": "The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The human [E1]Imp3[/E1] and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 [E2]snoRNA[/E2] in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp3", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "snoRNA", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "pm0114346", "entity_2_type_id": 70}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s0_HPRD50.d20.s0.p2", "text": "The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The human Imp3 and [E1]Imp4[/E1] proteins form a ternary complex with hMpp10, which only interacts with the U3 [E2]snoRNA[/E2] in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp4", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "pm0104160||pm0117832", "entity_1_type_id": 69, "entity_2": "snoRNA", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "pm0114346", "entity_2_type_id": 70}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s1_HPRD50.d20.s1.p0", "text": "We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins Imp3 and Imp4", "text_with_entity_marker": "We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins [E1]Imp3[/E1] and [E2]Imp4[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp3", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp4", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "pm0104160||pm0117832", "entity_2_type_id": 69}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s2_HPRD50.d20.s2.p0", "text": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "text_with_entity_marker": "The results of complementation experiments show that, in contrast to mouse [E1]Imp4[/E1], mouse [E2]Imp3[/E2] can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp4", "entity_1_idx": [[75, 79]], "entity_1_idx_in_text_with_entity_marker": [79, 83], "entity_1_type": "pm0104160||pm0117832", "entity_1_type_id": 69, "entity_2": "Imp3", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "pm0100548||pm0102353||pm0121765", "entity_2_type_id": 68}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s2_HPRD50.d20.s2.p1", "text": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "text_with_entity_marker": "The results of complementation experiments show that, in contrast to mouse [E1]Imp4[/E1], mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of [E2]Imp3[/E2] in pre-rRNA processing is evolutionarily conserved", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp4", "entity_1_idx": [[75, 79]], "entity_1_idx_in_text_with_entity_marker": [79, 83], "entity_1_type": "pm0104160||pm0117832", "entity_1_type_id": 69, "entity_2": "Imp3", "entity_2_idx": [[202, 206]], "entity_2_idx_in_text_with_entity_marker": [215, 219], "entity_2_type": "pm0100548||pm0102353||pm0121765", "entity_2_type_id": 68}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s2_HPRD50.d20.s2.p2", "text": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "text_with_entity_marker": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse [E1]Imp3[/E1] can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of [E2]Imp3[/E2] in pre-rRNA processing is evolutionarily conserved", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp3", "entity_1_idx": [[87, 91]], "entity_1_idx_in_text_with_entity_marker": [91, 95], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp3", "entity_2_idx": [[202, 206]], "entity_2_idx_in_text_with_entity_marker": [215, 219], "entity_2_type": "pm0100548||pm0102353||pm0121765", "entity_2_type_id": 68}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s3_HPRD50.d20.s3.p0", "text": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human [E1]Imp3[/E1] and [E2]Imp4[/E2] proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp3", "entity_1_idx": [[104, 108]], "entity_1_idx_in_text_with_entity_marker": [108, 112], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp4", "entity_2_idx": [[113, 117]], "entity_2_idx_in_text_with_entity_marker": [126, 130], "entity_2_type": "pm0104160||pm0117832", "entity_2_type_id": 69}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s3_HPRD50.d20.s3.p1", "text": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human [E1]Imp3[/E1] and Imp4 proteins predominantly interact with the U3 [E2]snoRNA[/E2] in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp3", "entity_1_idx": [[104, 108]], "entity_1_idx_in_text_with_entity_marker": [108, 112], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "snoRNA", "entity_2_idx": [[162, 168]], "entity_2_idx_in_text_with_entity_marker": [175, 181], "entity_2_type": "pm0114346", "entity_2_type_id": 70}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s3_HPRD50.d20.s3.p2", "text": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and [E1]Imp4[/E1] proteins predominantly interact with the U3 [E2]snoRNA[/E2] in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp4", "entity_1_idx": [[113, 117]], "entity_1_idx_in_text_with_entity_marker": [117, 121], "entity_1_type": "pm0104160||pm0117832", "entity_1_type_id": 69, "entity_2": "snoRNA", "entity_2_idx": [[162, 168]], "entity_2_idx_in_text_with_entity_marker": [175, 181], "entity_2_type": "pm0114346", "entity_2_type_id": 70}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s0_HPRD50.d21.s0.p0", "text": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system", "text_with_entity_marker": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor [E1]CB1[/E1] and the [E2]orexin 1 receptor[/E2] (OX1R) using a heterologous system", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CB1", "entity_1_idx": [[90, 93]], "entity_1_idx_in_text_with_entity_marker": [94, 97], "entity_1_type": "pm0109721", "entity_1_type_id": 71, "entity_2": "orexin 1 receptor", "entity_2_idx": [[102, 119]], "entity_2_idx_in_text_with_entity_marker": [115, 132], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s0_HPRD50.d21.s0.p2", "text": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system", "text_with_entity_marker": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the [E1]orexin 1 receptor[/E1] ([E2]OX1R[/E2]) using a heterologous system", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "orexin 1 receptor", "entity_1_idx": [[102, 119]], "entity_1_idx_in_text_with_entity_marker": [106, 123], "entity_1_type": "pm0111533", "entity_1_type_id": 72, "entity_2": "OX1R", "entity_2_idx": [[121, 125]], "entity_2_idx_in_text_with_entity_marker": [134, 138], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s1_HPRD50.d21.s1.p0", "text": "In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R", "text_with_entity_marker": "In contrast to [E1]OX1R[/E1], the potency of direct activation of [E2]CB1[/E2] was not affected by co-expression with OX1R", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "OX1R", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "pm0111533", "entity_1_type_id": 72, "entity_2": "CB1", "entity_2_idx": [[57, 60]], "entity_2_idx_in_text_with_entity_marker": [70, 73], "entity_2_type": "pm0109721", "entity_2_type_id": 71}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s1_HPRD50.d21.s1.p1", "text": "In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R", "text_with_entity_marker": "In contrast to [E1]OX1R[/E1], the potency of direct activation of CB1 was not affected by co-expression with [E2]OX1R[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "OX1R", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "pm0111533", "entity_1_type_id": 72, "entity_2": "OX1R", "entity_2_idx": [[100, 104]], "entity_2_idx_in_text_with_entity_marker": [113, 117], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s1_HPRD50.d21.s1.p2", "text": "In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R", "text_with_entity_marker": "In contrast to OX1R, the potency of direct activation of [E1]CB1[/E1] was not affected by co-expression with [E2]OX1R[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CB1", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [61, 64], "entity_1_type": "pm0109721", "entity_1_type_id": 71, "entity_2": "OX1R", "entity_2_idx": [[100, 104]], "entity_2_idx_in_text_with_entity_marker": [113, 117], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s2_HPRD50.d21.s2.p0", "text": "In addition, electron microscopy experiments revealed that CB1 and OX1R are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers", "text_with_entity_marker": "In addition, electron microscopy experiments revealed that [E1]CB1[/E1] and [E2]OX1R[/E2] are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CB1", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "pm0109721", "entity_1_type_id": 71, "entity_2": "OX1R", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p0", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "[E1]GC-GAP[/E1], a Rho family [E2]GTPase-activating protein[/E2] that interacts with signaling adapters Gab1 and Gab2", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GC-GAP", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "GTPase-activating protein", "entity_2_idx": [[21, 46]], "entity_2_idx_in_text_with_entity_marker": [34, 59], "entity_2_type": "pm0112603", "entity_2_type_id": 74}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p1", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "[E1]GC-GAP[/E1], a Rho family GTPase-activating protein that interacts with signaling adapters [E2]Gab1[/E2] and Gab2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Gab1", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "pm0112697", "entity_2_type_id": 75}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p2", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "[E1]GC-GAP[/E1], a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and [E2]Gab2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Gab2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "pm0111574", "entity_2_type_id": 76}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p3", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "GC-GAP, a Rho family [E1]GTPase-activating protein[/E1] that interacts with signaling adapters [E2]Gab1[/E2] and Gab2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GTPase-activating protein", "entity_1_idx": [[21, 46]], "entity_1_idx_in_text_with_entity_marker": [25, 50], "entity_1_type": "pm0112603", "entity_1_type_id": 74, "entity_2": "Gab1", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "pm0112697", "entity_2_type_id": 75}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p4", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "GC-GAP, a Rho family [E1]GTPase-activating protein[/E1] that interacts with signaling adapters Gab1 and [E2]Gab2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GTPase-activating protein", "entity_1_idx": [[21, 46]], "entity_1_idx_in_text_with_entity_marker": [25, 50], "entity_1_type": "pm0112603", "entity_1_type_id": 74, "entity_2": "Gab2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "pm0111574", "entity_2_type_id": 76}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p5", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters [E1]Gab1[/E1] and [E2]Gab2[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gab1", "entity_1_idx": [[86, 90]], "entity_1_idx_in_text_with_entity_marker": [90, 94], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Gab2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "pm0111574", "entity_2_type_id": 76}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p0", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "[E1]Gab1[/E1] and [E2]Gab2[/E2] are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gab1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Gab2", "entity_2_idx": [[9, 13]], "entity_2_idx_in_text_with_entity_marker": [22, 26], "entity_2_type": "pm0111574", "entity_2_type_id": 76}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p2", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "[E1]Gab1[/E1] and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, [E2]Shp-2[/E2], phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Shp-2", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "pm0122382", "entity_2_type_id": 78}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p3", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "[E1]Gab1[/E1] and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, [E2]phosphatidylinositol 3-kinase[/E2], Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[166, 195]], "entity_2_idx_in_text_with_entity_marker": [179, 208], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p4", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and [E1]Gab2[/E1] are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as [E2]Grb2[/E2], Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "Grb2", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "pm0105419", "entity_2_type_id": 77}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p5", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and [E1]Gab2[/E1] are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, [E2]Shp-2[/E2], phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "Shp-2", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "pm0122382", "entity_2_type_id": 78}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p6", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and [E1]Gab2[/E1] are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, [E2]phosphatidylinositol 3-kinase[/E2], Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[166, 195]], "entity_2_idx_in_text_with_entity_marker": [179, 208], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p7", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as [E1]Grb2[/E1], [E2]Shp-2[/E2], phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[153, 157]], "entity_1_idx_in_text_with_entity_marker": [157, 161], "entity_1_type": "pm0105419", "entity_1_type_id": 77, "entity_2": "Shp-2", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "pm0122382", "entity_2_type_id": 78}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p8", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as [E1]Grb2[/E1], Shp-2, [E2]phosphatidylinositol 3-kinase[/E2], Shc, and Crk", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[153, 157]], "entity_1_idx_in_text_with_entity_marker": [157, 161], "entity_1_type": "pm0105419", "entity_1_type_id": 77, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[166, 195]], "entity_2_idx_in_text_with_entity_marker": [179, 208], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p9", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, [E1]Shp-2[/E1], [E2]phosphatidylinositol 3-kinase[/E2], Shc, and Crk", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Shp-2", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "pm0122382", "entity_1_type_id": 78, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[166, 195]], "entity_2_idx_in_text_with_entity_marker": [179, 208], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s2_HPRD50.d22.s2.p0", "text": "In addition, GC-GAP contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length Nck in vitro", "text_with_entity_marker": "In addition, [E1]GC-GAP[/E1] contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length [E2]Nck[/E2] in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[13, 19]], "entity_1_idx_in_text_with_entity_marker": [17, 23], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Nck", "entity_2_idx": [[132, 135]], "entity_2_idx_in_text_with_entity_marker": [145, 148], "entity_2_type": "pm0121922", "entity_2_type_id": 79}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p0", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that [E1]Gab1[/E1] and [E2]Gab2[/E2] in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gab1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Gab2", "entity_2_idx": [[25, 29]], "entity_2_idx_in_text_with_entity_marker": [38, 42], "entity_2_type": "pm0111574", "entity_2_type_id": 76}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p1", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that [E1]Gab1[/E1] and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of [E2]GC-GAP[/E2] under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "GC-GAP", "entity_2_idx": [[118, 124]], "entity_2_idx_in_text_with_entity_marker": [131, 137], "entity_2_type": "pm0122639", "entity_2_type_id": 73}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p2", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that [E1]Gab1[/E1] and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and [E2]Cdc42[/E2] activities", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Cdc42", "entity_2_idx": [[186, 191]], "entity_2_idx_in_text_with_entity_marker": [199, 204], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p3", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that Gab1 and [E1]Gab2[/E1] in cooperation with other adapter molecules might regulate the cellular localization of [E2]GC-GAP[/E2] under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "GC-GAP", "entity_2_idx": [[118, 124]], "entity_2_idx_in_text_with_entity_marker": [131, 137], "entity_2_type": "pm0122639", "entity_2_type_id": 73}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p4", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that Gab1 and [E1]Gab2[/E1] in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and [E2]Cdc42[/E2] activities", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "Cdc42", "entity_2_idx": [[186, 191]], "entity_2_idx_in_text_with_entity_marker": [199, 204], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p5", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of [E1]GC-GAP[/E1] under specific stimuli, acting to regulate precisely Rac and [E2]Cdc42[/E2] activities", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GC-GAP", "entity_1_idx": [[118, 124]], "entity_1_idx_in_text_with_entity_marker": [122, 128], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Cdc42", "entity_2_idx": [[186, 191]], "entity_2_idx_in_text_with_entity_marker": [199, 204], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s4_HPRD50.d22.s4.p0", "text": "This work led to identification of a novel GTPase-activating protein (GAP) for Rho family GTPases", "text_with_entity_marker": "This work led to identification of a novel [E1]GTPase-activating protein[/E1] ([E2]GAP[/E2]) for Rho family GTPases", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GTPase-activating protein", "entity_1_idx": [[43, 68]], "entity_1_idx_in_text_with_entity_marker": [47, 72], "entity_1_type": "pm0112603", "entity_1_type_id": 74, "entity_2": "GAP", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "pm0112603||pm0113293", "entity_2_type_id": 81}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s5_HPRD50.d22.s5.p0", "text": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro", "text_with_entity_marker": "The GAP domain shows high similarity to the recently cloned [E1]CdGAP[/E1] and displays activity toward RhoA, [E2]Rac1[/E2], and Cdc42 in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CdGAP", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "pm0102116", "entity_1_type_id": 82, "entity_2": "Rac1", "entity_2_idx": [[101, 105]], "entity_2_idx_in_text_with_entity_marker": [114, 118], "entity_2_type": "pm0109115", "entity_2_type_id": 83}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s5_HPRD50.d22.s5.p1", "text": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro", "text_with_entity_marker": "The GAP domain shows high similarity to the recently cloned [E1]CdGAP[/E1] and displays activity toward RhoA, Rac1, and [E2]Cdc42[/E2] in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CdGAP", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "pm0102116", "entity_1_type_id": 82, "entity_2": "Cdc42", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s5_HPRD50.d22.s5.p2", "text": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro", "text_with_entity_marker": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, [E1]Rac1[/E1], and [E2]Cdc42[/E2] in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rac1", "entity_1_idx": [[101, 105]], "entity_1_idx_in_text_with_entity_marker": [105, 109], "entity_1_type": "pm0109115", "entity_1_type_id": 83, "entity_2": "Cdc42", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s6_HPRD50.d22.s6.p0", "text": "The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42", "text_with_entity_marker": "The protein was named [E1]GC-GAP[/E1] for its ability to interact with [E2]GAB[/E2] proteins and its activity toward Rac and Cdc42", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[22, 28]], "entity_1_idx_in_text_with_entity_marker": [26, 32], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "GAB", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [75, 78], "entity_2_type": "pm0100534", "entity_2_type_id": 84}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s6_HPRD50.d22.s6.p1", "text": "The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42", "text_with_entity_marker": "The protein was named [E1]GC-GAP[/E1] for its ability to interact with GAB proteins and its activity toward Rac and [E2]Cdc42[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[22, 28]], "entity_1_idx_in_text_with_entity_marker": [26, 32], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Cdc42", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s6_HPRD50.d22.s6.p2", "text": "The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42", "text_with_entity_marker": "The protein was named GC-GAP for its ability to interact with [E1]GAB[/E1] proteins and its activity toward Rac and [E2]Cdc42[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAB", "entity_1_idx": [[62, 65]], "entity_1_idx_in_text_with_entity_marker": [66, 69], "entity_1_type": "pm0100534", "entity_1_type_id": 84, "entity_2": "Cdc42", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s7_HPRD50.d22.s7.p0", "text": "Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA", "text_with_entity_marker": "Expression of [E1]GC-GAP[/E1] in 293T cells led to a reduction in active [E2]Rac1[/E2] and Cdc42 levels but not RhoA", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[14, 20]], "entity_1_idx_in_text_with_entity_marker": [18, 24], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Rac1", "entity_2_idx": [[64, 68]], "entity_2_idx_in_text_with_entity_marker": [77, 81], "entity_2_type": "pm0109115", "entity_2_type_id": 83}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s7_HPRD50.d22.s7.p1", "text": "Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA", "text_with_entity_marker": "Expression of [E1]GC-GAP[/E1] in 293T cells led to a reduction in active Rac1 and [E2]Cdc42[/E2] levels but not RhoA", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[14, 20]], "entity_1_idx_in_text_with_entity_marker": [18, 24], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Cdc42", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s7_HPRD50.d22.s7.p2", "text": "Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA", "text_with_entity_marker": "Expression of GC-GAP in 293T cells led to a reduction in active [E1]Rac1[/E1] and [E2]Cdc42[/E2] levels but not RhoA", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rac1", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "pm0109115", "entity_1_type_id": 83, "entity_2": "Cdc42", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s0_HPRD50.d23.s0.p0", "text": "A role for Plk1 phosphorylation of NudC in cytokinesis", "text_with_entity_marker": "A role for [E1]Plk1[/E1] phosphorylation of [E2]NudC[/E2] in cytokinesis", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[35, 39]], "entity_2_idx_in_text_with_entity_marker": [48, 52], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p0", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and [E2]NudC[/E2], show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p1", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and NudC, show that [E2]Plk1[/E2] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "Plk1", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p2", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and NudC, show that Plk1 phosphorylates [E2]NudC[/E2] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p3", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that [E2]NudC[/E2] is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p4", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p5", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and [E1]NudC[/E1], show that [E2]Plk1[/E2] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p6", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and [E1]NudC[/E1], show that Plk1 phosphorylates [E2]NudC[/E2] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p7", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and [E1]NudC[/E1], show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that [E2]NudC[/E2] is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p8", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and [E1]NudC[/E1], show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p9", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that [E1]Plk1[/E1] phosphorylates [E2]NudC[/E2] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p10", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that [E1]Plk1[/E1] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that [E2]NudC[/E2] is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p11", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that [E1]Plk1[/E1] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p12", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates [E1]NudC[/E1] at conserved S274 and S326 residues in vitro, and present evidence that [E2]NudC[/E2] is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [95, 99], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p13", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates [E1]NudC[/E1] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [95, 99], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p14", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that [E1]NudC[/E1] is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "NudC", "entity_1_idx": [[168, 172]], "entity_1_idx_in_text_with_entity_marker": [172, 176], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p0", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of [E1]NudC[/E1] by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type [E2]NudC[/E2], but not by NudC with mutations in the Plk1 phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[200, 204]], "entity_2_idx_in_text_with_entity_marker": [213, 217], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p1", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of [E1]NudC[/E1] by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by [E2]NudC[/E2] with mutations in the Plk1 phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[217, 221]], "entity_2_idx_in_text_with_entity_marker": [230, 234], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p2", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of [E1]NudC[/E1] by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the [E2]Plk1[/E2] phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p3", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type [E1]NudC[/E1], but not by [E2]NudC[/E2] with mutations in the Plk1 phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[200, 204]], "entity_1_idx_in_text_with_entity_marker": [204, 208], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[217, 221]], "entity_2_idx_in_text_with_entity_marker": [230, 234], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p4", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type [E1]NudC[/E1], but not by NudC with mutations in the [E2]Plk1[/E2] phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[200, 204]], "entity_1_idx_in_text_with_entity_marker": [204, 208], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s3_HPRD50.d23.s3.p0", "text": "These results suggest that Plk1 phosphorylation of NudC may influence cytokinesis", "text_with_entity_marker": "These results suggest that [E1]Plk1[/E1] phosphorylation of [E2]NudC[/E2] may influence cytokinesis", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[51, 55]], "entity_2_idx_in_text_with_entity_marker": [64, 68], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s0_HPRD50.d24.s0.p0", "text": "Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene", "text_with_entity_marker": "Specific interaction of [E1]Egr1[/E1] and c/EBPbeta leads to the transcriptional activation of the human [E2]low density lipoprotein receptor[/E2] gene", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Egr1", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "pm0115655", "entity_1_type_id": 87, "entity_2": "low density lipoprotein receptor", "entity_2_idx": [[96, 128]], "entity_2_idx_in_text_with_entity_marker": [109, 141], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p0", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the [E1]LDL receptor[/E1] ([E2]LDLR[/E2]) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LDL receptor", "entity_1_idx": [[56, 68]], "entity_1_idx_in_text_with_entity_marker": [60, 72], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "LDLR", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p1", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the [E1]LDL receptor[/E1] (LDLR) promoter mediates [E2]oncostatin M[/E2] (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LDL receptor", "entity_1_idx": [[56, 68]], "entity_1_idx_in_text_with_entity_marker": [60, 72], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "oncostatin M", "entity_2_idx": [[94, 106]], "entity_2_idx_in_text_with_entity_marker": [107, 119], "entity_2_type": "pm0100359", "entity_2_type_id": 89}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p2", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the [E1]LDL receptor[/E1] (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the [E2]LDLR[/E2] gene through a cholesterol-independent pathway", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LDL receptor", "entity_1_idx": [[56, 68]], "entity_1_idx_in_text_with_entity_marker": [60, 72], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "LDLR", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p3", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the LDL receptor ([E1]LDLR[/E1]) promoter mediates [E2]oncostatin M[/E2] (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LDLR", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "oncostatin M", "entity_2_idx": [[94, 106]], "entity_2_idx_in_text_with_entity_marker": [107, 119], "entity_2_type": "pm0100359", "entity_2_type_id": 89}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p4", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the LDL receptor ([E1]LDLR[/E1]) promoter mediates oncostatin M (OM)-induced transcription of the [E2]LDLR[/E2] gene through a cholesterol-independent pathway", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LDLR", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "LDLR", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p5", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates [E1]oncostatin M[/E1] (OM)-induced transcription of the [E2]LDLR[/E2] gene through a cholesterol-independent pathway", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "oncostatin M", "entity_1_idx": [[94, 106]], "entity_1_idx_in_text_with_entity_marker": [98, 110], "entity_1_type": "pm0100359", "entity_1_type_id": 89, "entity_2": "LDLR", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s0_HPRD50.d25.s0.p0", "text": "TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3", "text_with_entity_marker": "[E1]TR2[/E1] orphan receptor functions as negative modulator for [E2]androgen receptor[/E2] in prostate cancer cells PC-3", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR2", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "androgen receptor", "entity_2_idx": [[56, 73]], "entity_2_idx_in_text_with_entity_marker": [69, 86], "entity_2_type": "pm0125088", "entity_2_type_id": 91}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s0_HPRD50.d25.s0.p1", "text": "TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3", "text_with_entity_marker": "[E1]TR2[/E1] orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells [E2]PC-3[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "PC-3", "entity_2_idx": [[99, 103]], "entity_2_idx_in_text_with_entity_marker": [112, 116], "entity_2_type": "pm0107379||pm0107715||pm0114827", "entity_2_type_id": 13}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s0_HPRD50.d25.s0.p2", "text": "TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3", "text_with_entity_marker": "TR2 orphan receptor functions as negative modulator for [E1]androgen receptor[/E1] in prostate cancer cells [E2]PC-3[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "androgen receptor", "entity_1_idx": [[56, 73]], "entity_1_idx_in_text_with_entity_marker": [60, 77], "entity_1_type": "pm0125088", "entity_1_type_id": 91, "entity_2": "PC-3", "entity_2_idx": [[99, 103]], "entity_2_idx_in_text_with_entity_marker": [112, 116], "entity_2_type": "pm0107379||pm0107715||pm0114827", "entity_2_type_id": 13}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s1_HPRD50.d25.s1.p0", "text": "BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "text_with_entity_marker": "BACKGROUND: Both [E1]androgen receptor[/E1] (AR) and orphan receptor [E2]TR2[/E2] (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "androgen receptor", "entity_1_idx": [[17, 34]], "entity_1_idx_in_text_with_entity_marker": [21, 38], "entity_1_type": "pm0125088", "entity_1_type_id": 91, "entity_2": "TR2", "entity_2_idx": [[60, 63]], "entity_2_idx_in_text_with_entity_marker": [73, 76], "entity_2_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_2_type_id": 90}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s1_HPRD50.d25.s1.p1", "text": "BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "text_with_entity_marker": "BACKGROUND: Both [E1]androgen receptor[/E1] (AR) and orphan receptor TR2 ([E2]TR2[/E2]) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "androgen receptor", "entity_1_idx": [[17, 34]], "entity_1_idx_in_text_with_entity_marker": [21, 38], "entity_1_type": "pm0125088", "entity_1_type_id": 91, "entity_2": "TR2", "entity_2_idx": [[65, 68]], "entity_2_idx_in_text_with_entity_marker": [78, 81], "entity_2_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_2_type_id": 90}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s1_HPRD50.d25.s1.p2", "text": "BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "text_with_entity_marker": "BACKGROUND: Both androgen receptor (AR) and orphan receptor [E1]TR2[/E1] ([E2]TR2[/E2]) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "TR2", "entity_2_idx": [[65, 68]], "entity_2_idx_in_text_with_entity_marker": [78, 81], "entity_2_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_2_type_id": 90}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s2_HPRD50.d25.s2.p0", "text": "The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay", "text_with_entity_marker": "The interaction between AR and [E1]TR2[/E1] was assessed by [E2]glutathione-S-transferase[/E2] (GST) pull-down assay and mammalian two-hybrid system assay", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "glutathione-S-transferase", "entity_2_idx": [[51, 76]], "entity_2_idx_in_text_with_entity_marker": [64, 89], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s2_HPRD50.d25.s2.p1", "text": "The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay", "text_with_entity_marker": "The interaction between AR and [E1]TR2[/E1] was assessed by glutathione-S-transferase ([E2]GST[/E2]) pull-down assay and mammalian two-hybrid system assay", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "GST", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s2_HPRD50.d25.s2.p2", "text": "The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay", "text_with_entity_marker": "The interaction between AR and TR2 was assessed by [E1]glutathione-S-transferase[/E1] ([E2]GST[/E2]) pull-down assay and mammalian two-hybrid system assay", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "glutathione-S-transferase", "entity_1_idx": [[51, 76]], "entity_1_idx_in_text_with_entity_marker": [55, 80], "entity_1_type": "pm0116848", "entity_1_type_id": 31, "entity_2": "GST", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s0_HPRD50.d26.s0.p0", "text": "The protein pVHL functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Hif1 alpha for proteasomal degradation during normoxia", "text_with_entity_marker": "The protein [E1]pVHL[/E1] functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor [E2]Hif1 alpha[/E2] for proteasomal degradation during normoxia", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[122, 132]], "entity_2_idx_in_text_with_entity_marker": [135, 145], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s1_HPRD50.d26.s1.p0", "text": "We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome", "text_with_entity_marker": "We establish that [E1]pVHL[/E1] binds to [E2]Tat-binding protein-1[/E2] (TBP-1), a component of the 19S regulatory complex of the proteasome", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Tat-binding protein-1", "entity_2_idx": [[32, 53]], "entity_2_idx_in_text_with_entity_marker": [45, 66], "entity_2_type": "pm0113245", "entity_2_type_id": 94}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s1_HPRD50.d26.s1.p2", "text": "We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome", "text_with_entity_marker": "We establish that pVHL binds to [E1]Tat-binding protein-1[/E1] ([E2]TBP-1[/E2]), a component of the 19S regulatory complex of the proteasome", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Tat-binding protein-1", "entity_1_idx": [[32, 53]], "entity_1_idx_in_text_with_entity_marker": [36, 57], "entity_1_type": "pm0113245", "entity_1_type_id": 94, "entity_2": "TBP-1", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p1", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "[E1]TBP-1[/E1] associates with the beta-domain of pVHL and complexes with [E2]pVHL[/E2] and Hif1 alpha in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "pVHL", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p2", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "[E1]TBP-1[/E1] associates with the beta-domain of pVHL and complexes with pVHL and [E2]Hif1 alpha[/E2] in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[74, 84]], "entity_2_idx_in_text_with_entity_marker": [87, 97], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p3", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "TBP-1 associates with the beta-domain of [E1]pVHL[/E1] and complexes with [E2]pVHL[/E2] and Hif1 alpha in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "pVHL", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p4", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "TBP-1 associates with the beta-domain of [E1]pVHL[/E1] and complexes with pVHL and [E2]Hif1 alpha[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[74, 84]], "entity_2_idx_in_text_with_entity_marker": [87, 97], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p5", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "TBP-1 associates with the beta-domain of pVHL and complexes with [E1]pVHL[/E1] and [E2]Hif1 alpha[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[74, 84]], "entity_2_idx_in_text_with_entity_marker": [87, 97], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s3_HPRD50.d26.s3.p0", "text": "Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "text_with_entity_marker": "Overexpression of [E1]TBP-1[/E1] promotes degradation of [E2]Hif1 alpha[/E2] in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[48, 58]], "entity_2_idx_in_text_with_entity_marker": [61, 71], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s3_HPRD50.d26.s3.p1", "text": "Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "text_with_entity_marker": "Overexpression of [E1]TBP-1[/E1] promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of [E2]TBP-1[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP-1", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "TBP-1", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s3_HPRD50.d26.s3.p2", "text": "Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "text_with_entity_marker": "Overexpression of TBP-1 promotes degradation of [E1]Hif1 alpha[/E1] in a pVHL-dependent manner that requires the ATPase domain of [E2]TBP-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Hif1 alpha", "entity_1_idx": [[48, 58]], "entity_1_idx_in_text_with_entity_marker": [52, 62], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "TBP-1", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s4_HPRD50.d26.s4.p0", "text": "Blockade of TBP-1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Hif1 alpha", "text_with_entity_marker": "Blockade of [E1]TBP-1[/E1] expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of [E2]Hif1 alpha[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[103, 113]], "entity_2_idx_in_text_with_entity_marker": [116, 126], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s5_HPRD50.d26.s5.p1", "text": "Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1", "text_with_entity_marker": "Several distinct mutations in exon 2 of [E1]VHL[/E1] disrupt binding of pVHL to [E2]TBP-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "VHL", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "TBP-1", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p0", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A [E1]pVHL[/E1] mutant containing a P154L substitution coimmunoprecipitates with [E2]Hif1 alpha[/E2], but not TBP-1, and does not promote degradation of Hif1 alpha", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[2, 6]], "entity_1_idx_in_text_with_entity_marker": [6, 10], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p3", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with [E1]Hif1 alpha[/E1], but not [E2]TBP-1[/E2], and does not promote degradation of Hif1 alpha", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[72, 82]], "entity_1_idx_in_text_with_entity_marker": [76, 86], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "TBP-1", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p4", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with [E1]Hif1 alpha[/E1], but not TBP-1, and does not promote degradation of [E2]Hif1 alpha[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[72, 82]], "entity_1_idx_in_text_with_entity_marker": [76, 86], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "Hif1 alpha", "entity_2_idx": [[135, 145]], "entity_2_idx_in_text_with_entity_marker": [148, 158], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p5", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not [E1]TBP-1[/E1], and does not promote degradation of [E2]Hif1 alpha[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP-1", "entity_1_idx": [[92, 97]], "entity_1_idx_in_text_with_entity_marker": [96, 101], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[135, 145]], "entity_2_idx_in_text_with_entity_marker": [148, 158], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p0", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade [E2]Hif1 alpha[/E2] depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[37, 47]], "entity_2_idx_in_text_with_entity_marker": [50, 60], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p1", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade Hif1 alpha depends in part on its interaction with [E2]TBP-1[/E2] and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "TBP-1", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p2", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for [E2]Hif1 alpha[/E2] stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p3", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some [E2]pVHL[/E2]-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "pVHL", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p6", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade [E1]Hif1 alpha[/E1] depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some [E2]pVHL[/E2]-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[37, 47]], "entity_1_idx_in_text_with_entity_marker": [41, 51], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "pVHL", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p7", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with [E1]TBP-1[/E1] and suggests a new mechanism for [E2]Hif1 alpha[/E2] stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP-1", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p8", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with [E1]TBP-1[/E1] and suggests a new mechanism for Hif1 alpha stabilization in some [E2]pVHL[/E2]-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP-1", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "pVHL", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p9", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for [E1]Hif1 alpha[/E1] stabilization in some [E2]pVHL[/E2]-deficient tumors", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Hif1 alpha", "entity_1_idx": [[127, 137]], "entity_1_idx_in_text_with_entity_marker": [131, 141], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "pVHL", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p0", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "[E1]Pinin[/E1]/[E2]DRS[/E2]/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Pinin", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "DRS", "entity_2_idx": [[6, 9]], "entity_2_idx_in_text_with_entity_marker": [19, 22], "entity_2_type": "pm0118763", "entity_2_type_id": 96}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p1", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "[E1]Pinin[/E1]/DRS/memA interacts with [E2]SRp75[/E2], SRm300 and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Pinin", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "SRp75", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "pm0111657", "entity_2_type_id": 97}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p2", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "[E1]Pinin[/E1]/DRS/memA interacts with SRp75, [E2]SRm300[/E2] and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Pinin", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "SRm300", "entity_2_idx": [[37, 43]], "entity_2_idx_in_text_with_entity_marker": [50, 56], "entity_2_type": "pm0117461", "entity_2_type_id": 98}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p3", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "Pinin/[E1]DRS[/E1]/memA interacts with [E2]SRp75[/E2], SRm300 and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DRS", "entity_1_idx": [[6, 9]], "entity_1_idx_in_text_with_entity_marker": [10, 13], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "SRp75", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "pm0111657", "entity_2_type_id": 97}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p5", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "Pinin/DRS/memA interacts with [E1]SRp75[/E1], [E2]SRm300[/E2] and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRp75", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "pm0111657", "entity_1_type_id": 97, "entity_2": "SRm300", "entity_2_idx": [[37, 43]], "entity_2_idx_in_text_with_entity_marker": [50, 56], "entity_2_type": "pm0117461", "entity_2_type_id": 98}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s1_HPRD50.d27.s1.p0", "text": "Three SR-rich proteins were identified that interact with the C-terminus of Pnn: SRp75 and SRm300, known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130", "text_with_entity_marker": "Three SR-rich proteins were identified that interact with the C-terminus of Pnn: [E1]SRp75[/E1] and [E2]SRm300[/E2], known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRp75", "entity_1_idx": [[81, 86]], "entity_1_idx_in_text_with_entity_marker": [85, 90], "entity_1_type": "pm0111657", "entity_1_type_id": 97, "entity_2": "SRm300", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "pm0117461", "entity_2_type_id": 98}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s0_HPRD50.d28.s0.p0", "text": "We report that MSH2 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Chk1 and SMC1 (structure maintenance of chromosome 1)", "text_with_entity_marker": "We report that [E1]MSH2[/E1] (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of [E2]Chk1[/E2] and SMC1 (structure maintenance of chromosome 1)", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "pm0121865", "entity_1_type_id": 99, "entity_2": "Chk1", "entity_2_idx": [[162, 166]], "entity_2_idx_in_text_with_entity_marker": [175, 179], "entity_2_type": "pm0113524", "entity_2_type_id": 100}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s0_HPRD50.d28.s0.p1", "text": "We report that MSH2 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Chk1 and SMC1 (structure maintenance of chromosome 1)", "text_with_entity_marker": "We report that [E1]MSH2[/E1] (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Chk1 and [E2]SMC1[/E2] (structure maintenance of chromosome 1)", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "pm0121865", "entity_1_type_id": 99, "entity_2": "SMC1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s0_HPRD50.d28.s0.p2", "text": "We report that MSH2 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Chk1 and SMC1 (structure maintenance of chromosome 1)", "text_with_entity_marker": "We report that MSH2 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of [E1]Chk1[/E1] and [E2]SMC1[/E2] (structure maintenance of chromosome 1)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Chk1", "entity_1_idx": [[162, 166]], "entity_1_idx_in_text_with_entity_marker": [166, 170], "entity_1_type": "pm0113524", "entity_1_type_id": 100, "entity_2": "SMC1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s1_HPRD50.d28.s1.p0", "text": "We found that phosphorylation of Chk1 by ATR also requires checkpoint proteins Rad17 and replication protein A", "text_with_entity_marker": "We found that phosphorylation of [E1]Chk1[/E1] by ATR also requires checkpoint proteins [E2]Rad17[/E2] and replication protein A", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Chk1", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "pm0113524", "entity_1_type_id": 100, "entity_2": "Rad17", "entity_2_idx": [[79, 84]], "entity_2_idx_in_text_with_entity_marker": [92, 97], "entity_2_type": "pm0117336", "entity_2_type_id": 102}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s2_HPRD50.d28.s2.p0", "text": "In contrast, phosphorylation of SMC1 by ATR is independent of Rad17 and replication protein A, suggesting that the signaling pathway leading to SMC1 phosphorylation is distinct from that mediated by the checkpoint proteins", "text_with_entity_marker": "In contrast, phosphorylation of [E1]SMC1[/E1] by ATR is independent of [E2]Rad17[/E2] and replication protein A, suggesting that the signaling pathway leading to SMC1 phosphorylation is distinct from that mediated by the checkpoint proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC1", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "pm0116233", "entity_1_type_id": 101, "entity_2": "Rad17", "entity_2_idx": [[62, 67]], "entity_2_idx_in_text_with_entity_marker": [75, 80], "entity_2_type": "pm0117336", "entity_2_type_id": 102}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s2_HPRD50.d28.s2.p1", "text": "In contrast, phosphorylation of SMC1 by ATR is independent of Rad17 and replication protein A, suggesting that the signaling pathway leading to SMC1 phosphorylation is distinct from that mediated by the checkpoint proteins", "text_with_entity_marker": "In contrast, phosphorylation of [E1]SMC1[/E1] by ATR is independent of Rad17 and replication protein A, suggesting that the signaling pathway leading to [E2]SMC1[/E2] phosphorylation is distinct from that mediated by the checkpoint proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC1", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "pm0116233", "entity_1_type_id": 101, "entity_2": "SMC1", "entity_2_idx": [[144, 148]], "entity_2_idx_in_text_with_entity_marker": [157, 161], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s2_HPRD50.d28.s2.p2", "text": "In contrast, phosphorylation of SMC1 by ATR is independent of Rad17 and replication protein A, suggesting that the signaling pathway leading to SMC1 phosphorylation is distinct from that mediated by the checkpoint proteins", "text_with_entity_marker": "In contrast, phosphorylation of SMC1 by ATR is independent of [E1]Rad17[/E1] and replication protein A, suggesting that the signaling pathway leading to [E2]SMC1[/E2] phosphorylation is distinct from that mediated by the checkpoint proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rad17", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "pm0117336", "entity_1_type_id": 102, "entity_2": "SMC1", "entity_2_idx": [[144, 148]], "entity_2_idx_in_text_with_entity_marker": [157, 161], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s3_HPRD50.d28.s3.p0", "text": "In addition, both MSH2 and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "text_with_entity_marker": "In addition, both [E1]MSH2[/E1] and [E2]Rad17[/E2] are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MSH2", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0121865", "entity_1_type_id": 99, "entity_2": "Rad17", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "pm0117336", "entity_2_type_id": 102}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s3_HPRD50.d28.s3.p1", "text": "In addition, both MSH2 and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "text_with_entity_marker": "In addition, both [E1]MSH2[/E1] and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of [E2]SMC1[/E2] is required for cellular survival", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MSH2", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0121865", "entity_1_type_id": 99, "entity_2": "SMC1", "entity_2_idx": [[161, 165]], "entity_2_idx_in_text_with_entity_marker": [174, 178], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s3_HPRD50.d28.s3.p2", "text": "In addition, both MSH2 and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "text_with_entity_marker": "In addition, both MSH2 and [E1]Rad17[/E1] are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of [E2]SMC1[/E2] is required for cellular survival", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rad17", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "pm0117336", "entity_1_type_id": 102, "entity_2": "SMC1", "entity_2_idx": [[161, 165]], "entity_2_idx_in_text_with_entity_marker": [174, 178], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s0_HPRD50.d29.s0.p0", "text": "Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription", "text_with_entity_marker": "Modification of de novo DNA methyltransferase 3a ([E1]Dnmt3a[/E1]) by [E2]SUMO-1[/E2] modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[50, 56]], "entity_1_idx_in_text_with_entity_marker": [54, 60], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "SUMO-1", "entity_2_idx": [[61, 67]], "entity_2_idx_in_text_with_entity_marker": [74, 80], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p0", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E2]Ubc9[/E2] and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "Ubc9", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "pm0110323", "entity_2_type_id": 105}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p1", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases [E2]PIAS1[/E2] and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "PIAS1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "pm0117395", "entity_2_type_id": 106}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p2", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and [E2]PIASxalpha[/E2], all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "PIASxalpha", "entity_2_idx": [[167, 177]], "entity_2_idx_in_text_with_entity_marker": [180, 190], "entity_2_type": "pm0119764", "entity_2_type_id": 107}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p3", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, [E2]SUMO-1[/E2], to its target proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "SUMO-1", "entity_2_idx": [[267, 273]], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p4", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E1]Ubc9[/E1] and the E3 sumo ligases [E2]PIAS1[/E2] and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ubc9", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "pm0110323", "entity_1_type_id": 105, "entity_2": "PIAS1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "pm0117395", "entity_2_type_id": 106}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p5", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E1]Ubc9[/E1] and the E3 sumo ligases PIAS1 and [E2]PIASxalpha[/E2], all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ubc9", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "pm0110323", "entity_1_type_id": 105, "entity_2": "PIASxalpha", "entity_2_idx": [[167, 177]], "entity_2_idx_in_text_with_entity_marker": [180, 190], "entity_2_type": "pm0119764", "entity_2_type_id": 107}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p6", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E1]Ubc9[/E1] and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, [E2]SUMO-1[/E2], to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ubc9", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "pm0110323", "entity_1_type_id": 105, "entity_2": "SUMO-1", "entity_2_idx": [[267, 273]], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p7", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases [E1]PIAS1[/E1] and [E2]PIASxalpha[/E2], all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PIAS1", "entity_1_idx": [[157, 162]], "entity_1_idx_in_text_with_entity_marker": [161, 166], "entity_1_type": "pm0117395", "entity_1_type_id": 106, "entity_2": "PIASxalpha", "entity_2_idx": [[167, 177]], "entity_2_idx_in_text_with_entity_marker": [180, 190], "entity_2_type": "pm0119764", "entity_2_type_id": 107}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p8", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases [E1]PIAS1[/E1] and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, [E2]SUMO-1[/E2], to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PIAS1", "entity_1_idx": [[157, 162]], "entity_1_idx_in_text_with_entity_marker": [161, 166], "entity_1_type": "pm0117395", "entity_1_type_id": 106, "entity_2": "SUMO-1", "entity_2_idx": [[267, 273]], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p9", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and [E1]PIASxalpha[/E1], all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, [E2]SUMO-1[/E2], to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PIASxalpha", "entity_1_idx": [[167, 177]], "entity_1_idx_in_text_with_entity_marker": [171, 181], "entity_1_type": "pm0119764", "entity_1_type_id": 107, "entity_2": "SUMO-1", "entity_2_idx": [[267, 273]], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s2_HPRD50.d29.s2.p0", "text": "Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain", "text_with_entity_marker": "[E1]Dnmt3a[/E1] is modified by [E2]SUMO-1[/E2] in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "SUMO-1", "entity_2_idx": [[22, 28]], "entity_2_idx_in_text_with_entity_marker": [35, 41], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s2_HPRD50.d29.s2.p1", "text": "Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain", "text_with_entity_marker": "[E1]Dnmt3a[/E1] is modified by SUMO-1 in vivo and in vitro and the region of [E2]Dnmt3a[/E2] responsible for interaction maps to the N-terminal regulatory domain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Dnmt3a", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "Dnmt3a", "entity_2_idx": [[68, 74]], "entity_2_idx_in_text_with_entity_marker": [81, 87], "entity_2_type": "pm0106301", "entity_2_type_id": 103}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s2_HPRD50.d29.s2.p2", "text": "Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain", "text_with_entity_marker": "Dnmt3a is modified by [E1]SUMO-1[/E1] in vivo and in vitro and the region of [E2]Dnmt3a[/E2] responsible for interaction maps to the N-terminal regulatory domain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SUMO-1", "entity_1_idx": [[22, 28]], "entity_1_idx_in_text_with_entity_marker": [26, 32], "entity_1_type": "pm0108344", "entity_1_type_id": 104, "entity_2": "Dnmt3a", "entity_2_idx": [[68, 74]], "entity_2_idx_in_text_with_entity_marker": [81, 87], "entity_2_type": "pm0106301", "entity_2_type_id": 103}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s3_HPRD50.d29.s3.p0", "text": "Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b", "text_with_entity_marker": "Functionally, sumoylation of [E1]Dnmt3a[/E1] disrupts its ability to interact with histone deacetylases ([E2]HDAC1[/E2]/2), but not with another interaction partner, Dnmt3b", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "HDAC1", "entity_2_idx": [[96, 101]], "entity_2_idx_in_text_with_entity_marker": [109, 114], "entity_2_type": "pm0119729", "entity_2_type_id": 108}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s3_HPRD50.d29.s3.p1", "text": "Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b", "text_with_entity_marker": "Functionally, sumoylation of [E1]Dnmt3a[/E1] disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, [E2]Dnmt3b[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Dnmt3a", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "Dnmt3b", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "pm0126533", "entity_2_type_id": 109}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s3_HPRD50.d29.s3.p2", "text": "Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b", "text_with_entity_marker": "Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases ([E1]HDAC1[/E1]/2), but not with another interaction partner, [E2]Dnmt3b[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HDAC1", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "pm0119729", "entity_1_type_id": 108, "entity_2": "Dnmt3b", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "pm0126533", "entity_2_type_id": 109}], "directed": false, "reverse": false}
{"id": "HPRD50.d30.s0_HPRD50.d30.s0.p0", "text": "The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation", "text_with_entity_marker": "The tyrosine kinase [E1]Tyk-2[/E1] is physically associated with the Type I interferon ([E2]IFN[/E2]) receptor complex and is rapidly activated during IFN alpha stimulation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Tyk-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "pm0101504", "entity_1_type_id": 110, "entity_2": "IFN", "entity_2_idx": [[79, 82]], "entity_2_idx_in_text_with_entity_marker": [92, 95], "entity_2_type": "pm0111853", "entity_2_type_id": 111}], "directed": false, "reverse": false}
{"id": "HPRD50.d30.s0_HPRD50.d30.s0.p1", "text": "The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation", "text_with_entity_marker": "The tyrosine kinase [E1]Tyk-2[/E1] is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during [E2]IFN alpha[/E2] stimulation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Tyk-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "pm0101504", "entity_1_type_id": 110, "entity_2": "IFN alpha", "entity_2_idx": [[133, 142]], "entity_2_idx_in_text_with_entity_marker": [146, 155], "entity_2_type": "pm0111853", "entity_2_type_id": 111}], "directed": false, "reverse": false}
{"id": "HPRD50.d30.s0_HPRD50.d30.s0.p2", "text": "The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation", "text_with_entity_marker": "The tyrosine kinase Tyk-2 is physically associated with the Type I interferon ([E1]IFN[/E1]) receptor complex and is rapidly activated during [E2]IFN alpha[/E2] stimulation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "pm0111853", "entity_1_type_id": 111, "entity_2": "IFN alpha", "entity_2_idx": [[133, 142]], "entity_2_idx_in_text_with_entity_marker": [146, 155], "entity_2_type": "pm0111853", "entity_2_type_id": 111}], "directed": false, "reverse": false}
{"id": "HPRD50.d31.s0_HPRD50.d31.s0.p0", "text": "Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation", "text_with_entity_marker": "[E1]Raf1[/E1] interaction with [E2]Cdc25[/E2] phosphatase ties mitogenic signal transduction to cell cycle activation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0117803", "entity_1_type_id": 112, "entity_2": "Cdc25", "entity_2_idx": [[22, 27]], "entity_2_idx_in_text_with_entity_marker": [35, 40], "entity_2_type": "pm0106635||pm0109000", "entity_2_type_id": 113}], "directed": false, "reverse": false}
{"id": "HPRD50.d31.s1_HPRD50.d31.s1.p0", "text": "We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes", "text_with_entity_marker": "We show here that [E1]Cdc25[/E1] phosphatase associates with [E2]raf1[/E2] in somatic mammalian cells and in meiotic frog oocytes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdc25", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "pm0106635||pm0109000", "entity_1_type_id": 113, "entity_2": "raf1", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "pm0117803", "entity_2_type_id": 112}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p0", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans ([E1]perlecan[/E1], [E2]biglycan[/E2], decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "biglycan", "entity_2_idx": [[71, 79]], "entity_2_idx_in_text_with_entity_marker": [84, 92], "entity_2_type": "pm0124379", "entity_2_type_id": 115}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p1", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans ([E1]perlecan[/E1], biglycan, [E2]decorin[/E2], and versican) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "decorin", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p2", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans ([E1]perlecan[/E1], biglycan, decorin, and [E2]versican[/E2]) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "versican", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p3", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans (perlecan, [E1]biglycan[/E1], [E2]decorin[/E2], and versican) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[71, 79]], "entity_1_idx_in_text_with_entity_marker": [75, 83], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "decorin", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p4", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans (perlecan, [E1]biglycan[/E1], decorin, and [E2]versican[/E2]) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[71, 79]], "entity_1_idx_in_text_with_entity_marker": [75, 83], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "versican", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p5", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, [E1]decorin[/E1], and [E2]versican[/E2]) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[81, 88]], "entity_1_idx_in_text_with_entity_marker": [85, 92], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "versican", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p0", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of [E1]perlecan[/E1], a specific [E2]heparan sulfate proteoglycan[/E2], to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "heparan sulfate proteoglycan", "entity_2_idx": [[82, 110]], "entity_2_idx_in_text_with_entity_marker": [95, 123], "entity_2_type": "pm0112250", "entity_2_type_id": 118}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p1", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of [E1]perlecan[/E1], a specific heparan sulfate proteoglycan, to the [E2]beta-amyloid[/E2] protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "beta-amyloid", "entity_2_idx": [[119, 131]], "entity_2_idx_in_text_with_entity_marker": [132, 144], "entity_2_type": "beta-pm0104696", "entity_2_type_id": 119}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p2", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of [E1]perlecan[/E1], a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing [E2]amyloid[/E2] deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "amyloid", "entity_2_idx": [[160, 167]], "entity_2_idx_in_text_with_entity_marker": [173, 180], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p4", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of perlecan, a specific [E1]heparan sulfate proteoglycan[/E1], to the beta-amyloid protein (A beta)-containing [E2]amyloid[/E2] deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "heparan sulfate proteoglycan", "entity_1_idx": [[82, 110]], "entity_1_idx_in_text_with_entity_marker": [86, 114], "entity_1_type": "pm0112250", "entity_1_type_id": 118, "entity_2": "amyloid", "entity_2_idx": [[160, 167]], "entity_2_idx_in_text_with_entity_marker": [173, 180], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p5", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the [E1]beta-amyloid[/E1] protein (A beta)-containing [E2]amyloid[/E2] deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-amyloid", "entity_1_idx": [[119, 131]], "entity_1_idx_in_text_with_entity_marker": [123, 135], "entity_1_type": "beta-pm0104696", "entity_1_type_id": 119, "entity_2": "amyloid", "entity_2_idx": [[160, 167]], "entity_2_idx_in_text_with_entity_marker": [173, 180], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s2_HPRD50.d32.s2.p0", "text": "Overall, the results indicate that specific vascular cell-derived PGs differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of perlecan", "text_with_entity_marker": "Overall, the results indicate that specific vascular cell-derived [E1]PGs[/E1] differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of [E2]perlecan[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "perlecan", "entity_2_idx": [[249, 257]], "entity_2_idx_in_text_with_entity_marker": [262, 270], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p0", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell ([E1]SMC[/E1])-derived [E2]PGs[/E2] to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[130, 133]], "entity_1_idx_in_text_with_entity_marker": [134, 137], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "PGs", "entity_2_idx": [[143, 146]], "entity_2_idx_in_text_with_entity_marker": [156, 159], "entity_2_type": "pm0108066", "entity_2_type_id": 121}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p1", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell ([E1]SMC[/E1])-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular [E2]amyloid[/E2] deposits may be due to its interactions with perlecan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[130, 133]], "entity_1_idx_in_text_with_entity_marker": [134, 137], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "amyloid", "entity_2_idx": [[237, 244]], "entity_2_idx_in_text_with_entity_marker": [250, 257], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p2", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell ([E1]SMC[/E1])-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with [E2]perlecan[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[130, 133]], "entity_1_idx_in_text_with_entity_marker": [134, 137], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "perlecan", "entity_2_idx": [[290, 298]], "entity_2_idx_in_text_with_entity_marker": [303, 311], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p3", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived [E1]PGs[/E1] to A beta was examined to determine whether the accumulation of A beta in cerebrovascular [E2]amyloid[/E2] deposits may be due to its interactions with perlecan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[143, 146]], "entity_1_idx_in_text_with_entity_marker": [147, 150], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "amyloid", "entity_2_idx": [[237, 244]], "entity_2_idx_in_text_with_entity_marker": [250, 257], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p4", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived [E1]PGs[/E1] to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with [E2]perlecan[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[143, 146]], "entity_1_idx_in_text_with_entity_marker": [147, 150], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "perlecan", "entity_2_idx": [[290, 298]], "entity_2_idx_in_text_with_entity_marker": [303, 311], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p5", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular [E1]amyloid[/E1] deposits may be due to its interactions with [E2]perlecan[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "amyloid", "entity_1_idx": [[237, 244]], "entity_1_idx_in_text_with_entity_marker": [241, 248], "entity_1_type": "pm0104696", "entity_1_type_id": 120, "entity_2": "perlecan", "entity_2_idx": [[290, 298]], "entity_2_idx_in_text_with_entity_marker": [303, 311], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s4_HPRD50.d32.s4.p0", "text": "Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in perlecan which was partially removed by pretreatment with heparitinase, but not by chondroitin ABC lyase", "text_with_entity_marker": "Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in [E1]perlecan[/E1] which was partially removed by pretreatment with heparitinase, but not by chondroitin [E2]ABC[/E2] lyase", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[178, 186]], "entity_1_idx_in_text_with_entity_marker": [182, 190], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "ABC", "entity_2_idx": [[273, 276]], "entity_2_idx_in_text_with_entity_marker": [286, 289], "entity_2_type": "pm0102466", "entity_2_type_id": 123}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s5_HPRD50.d32.s5.p0", "text": "[35S]-Sulfate labeled proteoglycans (PGs) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine serum albumin", "text_with_entity_marker": "[35S]-Sulfate labeled proteoglycans ([E1]PGs[/E1]) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine [E2]serum albumin[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "serum albumin", "entity_2_idx": [[253, 266]], "entity_2_idx_in_text_with_entity_marker": [266, 279], "entity_2_type": "pm0103143", "entity_2_type_id": 124}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p0", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] [E2]PGs[/E2] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "PGs", "entity_2_idx": [[31, 34]], "entity_2_idx_in_text_with_entity_marker": [44, 47], "entity_2_type": "pm0108066", "entity_2_type_id": 121}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p1", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] PGs bound to A beta (1-28) revealed strong binding by [E2]perlecan[/E2], weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "perlecan", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p2", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E2]decorin[/E2] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "decorin", "entity_2_idx": [[111, 118]], "entity_2_idx_in_text_with_entity_marker": [124, 131], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p4", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p5", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p6", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by [E2]perlecan[/E2], weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "perlecan", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p7", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E2]decorin[/E2] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "decorin", "entity_2_idx": [[111, 118]], "entity_2_idx_in_text_with_entity_marker": [124, 131], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p8", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and [E2]biglycan[/E2], two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "biglycan", "entity_2_idx": [[123, 131]], "entity_2_idx_in_text_with_entity_marker": [136, 144], "entity_2_type": "pm0124379", "entity_2_type_id": 115}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p9", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p11", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by [E1]perlecan[/E1], weak binding by [E2]decorin[/E2] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "decorin", "entity_2_idx": [[111, 118]], "entity_2_idx_in_text_with_entity_marker": [124, 131], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p12", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by [E1]perlecan[/E1], weak binding by decorin and [E2]biglycan[/E2], two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "biglycan", "entity_2_idx": [[123, 131]], "entity_2_idx_in_text_with_entity_marker": [136, 144], "entity_2_type": "pm0124379", "entity_2_type_id": 115}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p14", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by [E1]perlecan[/E1], weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p15", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E1]decorin[/E1] and [E2]biglycan[/E2], two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[111, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 122], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "biglycan", "entity_2_idx": [[123, 131]], "entity_2_idx_in_text_with_entity_marker": [136, 144], "entity_2_type": "pm0124379", "entity_2_type_id": 115}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p16", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E1]decorin[/E1] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[111, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 122], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p17", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E1]decorin[/E1] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[111, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 122], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p18", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and [E1]biglycan[/E1], two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[123, 131]], "entity_1_idx_in_text_with_entity_marker": [127, 135], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p19", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and [E1]biglycan[/E1], two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[123, 131]], "entity_1_idx_in_text_with_entity_marker": [127, 135], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p20", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E1]versican[/E1]/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "versican", "entity_1_idx": [[192, 200]], "entity_1_idx_in_text_with_entity_marker": [196, 204], "entity_1_type": "pm0106611", "entity_1_type_id": 117, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s0_HPRD50.d33.s0.p0", "text": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "text_with_entity_marker": "Cross-linking of [E1]CD53[/E1] with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag [E2]CD69[/E2], increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD53", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "pm0107494", "entity_1_type_id": 125, "entity_2": "CD69", "entity_2_idx": [[226, 230]], "entity_2_idx_in_text_with_entity_marker": [239, 243], "entity_2_type": "pm0115739", "entity_2_type_id": 126}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s0_HPRD50.d33.s0.p1", "text": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "text_with_entity_marker": "Cross-linking of [E1]CD53[/E1] with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and [E2]c-myc[/E2] protein levels, and enhanced binding of 7-aminoactinomycin D", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD53", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "pm0107494", "entity_1_type_id": 125, "entity_2": "c-myc", "entity_2_idx": [[281, 286]], "entity_2_idx_in_text_with_entity_marker": [294, 299], "entity_2_type": "pm0104123", "entity_2_type_id": 127}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s0_HPRD50.d33.s0.p2", "text": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "text_with_entity_marker": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag [E1]CD69[/E1], increases in cellular volume, RNA synthesis, and [E2]c-myc[/E2] protein levels, and enhanced binding of 7-aminoactinomycin D", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD69", "entity_1_idx": [[226, 230]], "entity_1_idx_in_text_with_entity_marker": [230, 234], "entity_1_type": "pm0115739", "entity_1_type_id": 126, "entity_2": "c-myc", "entity_2_idx": [[281, 286]], "entity_2_idx_in_text_with_entity_marker": [294, 299], "entity_2_type": "pm0104123", "entity_2_type_id": 127}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s1_HPRD50.d33.s1.p0", "text": "However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53", "text_with_entity_marker": "However, cytokines, in particular [E1]IL-2[/E1] and [E2]IL-4[/E2], potentiated the DNA synthesis induced by cross-linking of CD53", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "pm0110478", "entity_1_type_id": 128, "entity_2": "IL-4", "entity_2_idx": [[43, 47]], "entity_2_idx_in_text_with_entity_marker": [56, 60], "entity_2_type": "pm0106845", "entity_2_type_id": 129}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s1_HPRD50.d33.s1.p1", "text": "However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53", "text_with_entity_marker": "However, cytokines, in particular [E1]IL-2[/E1] and IL-4, potentiated the DNA synthesis induced by cross-linking of [E2]CD53[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-2", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "pm0110478", "entity_1_type_id": 128, "entity_2": "CD53", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "pm0107494", "entity_2_type_id": 125}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s1_HPRD50.d33.s1.p2", "text": "However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53", "text_with_entity_marker": "However, cytokines, in particular IL-2 and [E1]IL-4[/E1], potentiated the DNA synthesis induced by cross-linking of [E2]CD53[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-4", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "pm0106845", "entity_1_type_id": 129, "entity_2": "CD53", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "pm0107494", "entity_2_type_id": 125}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s0_HPRD50.d34.s0.p0", "text": "The human apoB mRNA editing protein is a cytidine deaminase showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases", "text_with_entity_marker": "The human [E1]apoB[/E1] mRNA editing protein is a [E2]cytidine deaminase[/E2] showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "apoB", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "pm0126272", "entity_1_type_id": 130, "entity_2": "cytidine deaminase", "entity_2_idx": [[41, 59]], "entity_2_idx_in_text_with_entity_marker": [54, 72], "entity_2_type": "pm0107865", "entity_2_type_id": 131}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s1_HPRD50.d34.s1.p0", "text": "The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans", "text_with_entity_marker": "The fact that the [E1]apoB[/E1] mRNA editing protein also exists as a [E2]homodimer[/E2] has important implications for the mechanism of apoB mRNA editing in humans", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "apoB", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0126272", "entity_1_type_id": 130, "entity_2": "homodimer", "entity_2_idx": [[61, 70]], "entity_2_idx_in_text_with_entity_marker": [74, 83], "entity_2_type": "pm0125626", "entity_2_type_id": 132}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s1_HPRD50.d34.s1.p1", "text": "The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans", "text_with_entity_marker": "The fact that the [E1]apoB[/E1] mRNA editing protein also exists as a homodimer has important implications for the mechanism of [E2]apoB[/E2] mRNA editing in humans", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "apoB", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0126272", "entity_1_type_id": 130, "entity_2": "apoB", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "pm0126272", "entity_2_type_id": 130}], "directed": false, "reverse": false}
{"id": "HPRD50.d35.s0_HPRD50.d35.s0.p0", "text": "Assignment of Etfdh, Etfb, and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human", "text_with_entity_marker": "Assignment of [E1]Etfdh[/E1], [E2]Etfb[/E2], and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Etfdh", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "pm0103481", "entity_1_type_id": 133, "entity_2": "Etfb", "entity_2_idx": [[21, 25]], "entity_2_idx_in_text_with_entity_marker": [34, 38], "entity_2_type": "pm0110405", "entity_2_type_id": 134}], "directed": false, "reverse": false}
{"id": "HPRD50.d35.s1_HPRD50.d35.s1.p0", "text": "We used cDNA probes for the Etfdh, Etfb, and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13", "text_with_entity_marker": "We used cDNA probes for the [E1]Etfdh[/E1], [E2]Etfb[/E2], and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Etfdh", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "pm0103481", "entity_1_type_id": 133, "entity_2": "Etfb", "entity_2_idx": [[35, 39]], "entity_2_idx_in_text_with_entity_marker": [48, 52], "entity_2_type": "pm0110405", "entity_2_type_id": 134}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s0_HPRD50.d36.s0.p0", "text": "CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation", "text_with_entity_marker": "[E1]CD22[/E1] associates with [E2]protein tyrosine phosphatase 1C[/E2], Syk, and phospholipase C-gamma(1) upon B cell activation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "protein tyrosine phosphatase 1C", "entity_2_idx": [[21, 52]], "entity_2_idx_in_text_with_entity_marker": [34, 65], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s1_HPRD50.d36.s1.p0", "text": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for PTP-1C regulates tyrosyl phosphorylation of CD22", "text_with_entity_marker": "These results suggest that tyrosyl-phosphorylated [E1]CD22[/E1] may be a substrate for [E2]PTP-1C[/E2] regulates tyrosyl phosphorylation of CD22", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[78, 84]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s1_HPRD50.d36.s1.p1", "text": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for PTP-1C regulates tyrosyl phosphorylation of CD22", "text_with_entity_marker": "These results suggest that tyrosyl-phosphorylated [E1]CD22[/E1] may be a substrate for PTP-1C regulates tyrosyl phosphorylation of [E2]CD22[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD22", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "CD22", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s1_HPRD50.d36.s1.p2", "text": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for PTP-1C regulates tyrosyl phosphorylation of CD22", "text_with_entity_marker": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for [E1]PTP-1C[/E1] regulates tyrosyl phosphorylation of [E2]CD22[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTP-1C", "entity_1_idx": [[78, 84]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "CD22", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s2_HPRD50.d36.s2.p1", "text": "The association of PTP-1C with CD22 was mediated by the NH2-terminal Src homology 2 (SH2) domain of PTP-1C", "text_with_entity_marker": "The association of [E1]PTP-1C[/E1] with CD22 was mediated by the NH2-terminal Src homology 2 (SH2) domain of [E2]PTP-1C[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTP-1C", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "PTP-1C", "entity_2_idx": [[100, 106]], "entity_2_idx_in_text_with_entity_marker": [113, 119], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s2_HPRD50.d36.s2.p2", "text": "The association of PTP-1C with CD22 was mediated by the NH2-terminal Src homology 2 (SH2) domain of PTP-1C", "text_with_entity_marker": "The association of PTP-1C with [E1]CD22[/E1] was mediated by the NH2-terminal Src homology 2 (SH2) domain of [E2]PTP-1C[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[100, 106]], "entity_2_idx_in_text_with_entity_marker": [113, 119], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s3_HPRD50.d36.s3.p0", "text": "Complexes of either CD22/PTP-1C/Syk/PLC-gamma(1) could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively", "text_with_entity_marker": "Complexes of either [E1]CD22[/E1]/[E2]PTP-1C[/E2]/Syk/PLC-gamma(1) could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[25, 31]], "entity_2_idx_in_text_with_entity_marker": [38, 44], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s4_HPRD50.d36.s4.p0", "text": "Transient expression of CD22 and a null mutant of PTP-1C (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "text_with_entity_marker": "Transient expression of [E1]CD22[/E1] and a null mutant of [E2]PTP-1C[/E2] (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD22", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[50, 56]], "entity_2_idx_in_text_with_entity_marker": [63, 69], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s4_HPRD50.d36.s4.p1", "text": "Transient expression of CD22 and a null mutant of PTP-1C (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "text_with_entity_marker": "Transient expression of [E1]CD22[/E1] and a null mutant of PTP-1C (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of [E2]CD22[/E2] and its interaction with PTP-1CM", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD22", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "CD22", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s4_HPRD50.d36.s4.p2", "text": "Transient expression of CD22 and a null mutant of PTP-1C (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "text_with_entity_marker": "Transient expression of CD22 and a null mutant of [E1]PTP-1C[/E1] (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of [E2]CD22[/E2] and its interaction with PTP-1CM", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTP-1C", "entity_1_idx": [[50, 56]], "entity_1_idx_in_text_with_entity_marker": [54, 60], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "CD22", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s5_HPRD50.d36.s5.p0", "text": "By contrast, CD22 was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type PTP-1C", "text_with_entity_marker": "By contrast, [E1]CD22[/E1] was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type [E2]PTP-1C[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD22", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[105, 111]], "entity_2_idx_in_text_with_entity_marker": [118, 124], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p0", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "[E1]TFIID[/E1] dimers formed through self-association of the TATA-binding polypeptide ([E2]TBP[/E2]) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0109127", "entity_1_type_id": 137, "entity_2": "TBP", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0109127", "entity_2_type_id": 137}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p1", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "[E1]TFIID[/E1] dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to [E2]TAF(II)250[/E2], the core subunit of TFIID", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TFIID", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0109127", "entity_1_type_id": 137, "entity_2": "TAF(II)250", "entity_2_idx": [[142, 152]], "entity_2_idx_in_text_with_entity_marker": [155, 165], "entity_2_type": "pm0108292", "entity_2_type_id": 138}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p2", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "[E1]TFIID[/E1] dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of [E2]TFIID[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0109127", "entity_1_type_id": 137, "entity_2": "TFIID", "entity_2_idx": [[174, 179]], "entity_2_idx_in_text_with_entity_marker": [187, 192], "entity_2_type": "pm0109127", "entity_2_type_id": 137}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p3", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "TFIID dimers formed through self-association of the TATA-binding polypeptide ([E1]TBP[/E1]) subunit and could be immunoprecipitated with antibodies to [E2]TAF(II)250[/E2], the core subunit of TFIID", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "pm0109127", "entity_1_type_id": 137, "entity_2": "TAF(II)250", "entity_2_idx": [[142, 152]], "entity_2_idx_in_text_with_entity_marker": [155, 165], "entity_2_type": "pm0108292", "entity_2_type_id": 138}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p4", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "TFIID dimers formed through self-association of the TATA-binding polypeptide ([E1]TBP[/E1]) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of [E2]TFIID[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "pm0109127", "entity_1_type_id": 137, "entity_2": "TFIID", "entity_2_idx": [[174, 179]], "entity_2_idx_in_text_with_entity_marker": [187, 192], "entity_2_type": "pm0109127", "entity_2_type_id": 137}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p0", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including [E2]cystatin alpha[/E2], desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "cystatin alpha", "entity_2_idx": [[171, 185]], "entity_2_idx_in_text_with_entity_marker": [184, 198], "entity_2_type": "pm0104526", "entity_2_type_id": 140}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p1", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, [E2]desmoplakin[/E2], elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "desmoplakin", "entity_2_idx": [[187, 198]], "entity_2_idx_in_text_with_entity_marker": [200, 211], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p2", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, [E2]elafin[/E2], keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "elafin", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "pm0114270", "entity_2_type_id": 142}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p4", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p5", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], [E2]desmoplakin[/E2], elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "desmoplakin", "entity_2_idx": [[187, 198]], "entity_2_idx_in_text_with_entity_marker": [200, 211], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p6", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], desmoplakin, [E2]elafin[/E2], keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "elafin", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "pm0114270", "entity_2_type_id": 142}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p7", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], desmoplakin, elafin, keratins, members of the small proline-rich superfamily, [E2]loricrin[/E2], and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "loricrin", "entity_2_idx": [[265, 273]], "entity_2_idx_in_text_with_entity_marker": [278, 286], "entity_2_type": "pm0103809", "entity_2_type_id": 143}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p8", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p9", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, [E1]desmoplakin[/E1], [E2]elafin[/E2], keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "desmoplakin", "entity_1_idx": [[187, 198]], "entity_1_idx_in_text_with_entity_marker": [191, 202], "entity_1_type": "pm0110549", "entity_1_type_id": 141, "entity_2": "elafin", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "pm0114270", "entity_2_type_id": 142}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p10", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, [E1]desmoplakin[/E1], elafin, keratins, members of the small proline-rich superfamily, [E2]loricrin[/E2], and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "desmoplakin", "entity_1_idx": [[187, 198]], "entity_1_idx_in_text_with_entity_marker": [191, 202], "entity_1_type": "pm0110549", "entity_1_type_id": 141, "entity_2": "loricrin", "entity_2_idx": [[265, 273]], "entity_2_idx_in_text_with_entity_marker": [278, 286], "entity_2_type": "pm0103809", "entity_2_type_id": 143}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p11", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, [E1]desmoplakin[/E1], elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "desmoplakin", "entity_1_idx": [[187, 198]], "entity_1_idx_in_text_with_entity_marker": [191, 202], "entity_1_type": "pm0110549", "entity_1_type_id": 141, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p12", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, [E1]elafin[/E1], keratins, members of the small proline-rich superfamily, [E2]loricrin[/E2], and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elafin", "entity_1_idx": [[200, 206]], "entity_1_idx_in_text_with_entity_marker": [204, 210], "entity_1_type": "pm0114270", "entity_1_type_id": 142, "entity_2": "loricrin", "entity_2_idx": [[265, 273]], "entity_2_idx_in_text_with_entity_marker": [278, 286], "entity_2_type": "pm0103809", "entity_2_type_id": 143}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p13", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, [E1]elafin[/E1], keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elafin", "entity_1_idx": [[200, 206]], "entity_1_idx_in_text_with_entity_marker": [204, 210], "entity_1_type": "pm0114270", "entity_1_type_id": 142, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p14", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, [E1]loricrin[/E1], and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "loricrin", "entity_1_idx": [[265, 273]], "entity_1_idx_in_text_with_entity_marker": [269, 277], "entity_1_type": "pm0103809", "entity_1_type_id": 143, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s1_HPRD50.d38.s1.p0", "text": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "text_with_entity_marker": "Specific glutamines or lysines of [E1]involucrin[/E1] were used to cross-link the different proteins, such as glutamines 495 and 496 to [E2]desmoplakin[/E2], glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "involucrin", "entity_1_idx": [[34, 44]], "entity_1_idx_in_text_with_entity_marker": [38, 48], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "desmoplakin", "entity_2_idx": [[127, 138]], "entity_2_idx_in_text_with_entity_marker": [140, 151], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s1_HPRD50.d38.s1.p1", "text": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "text_with_entity_marker": "Specific glutamines or lysines of [E1]involucrin[/E1] were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain [E2]involucrin[/E2] cross-links", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "involucrin", "entity_1_idx": [[34, 44]], "entity_1_idx_in_text_with_entity_marker": [38, 48], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "involucrin", "entity_2_idx": [[239, 249]], "entity_2_idx_in_text_with_entity_marker": [252, 262], "entity_2_type": "pm0104308", "entity_2_type_id": 139}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s1_HPRD50.d38.s1.p2", "text": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "text_with_entity_marker": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to [E1]desmoplakin[/E1], glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain [E2]involucrin[/E2] cross-links", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "desmoplakin", "entity_1_idx": [[127, 138]], "entity_1_idx_in_text_with_entity_marker": [131, 142], "entity_1_type": "pm0110549", "entity_1_type_id": 141, "entity_2": "involucrin", "entity_2_idx": [[239, 249]], "entity_2_idx_in_text_with_entity_marker": [252, 262], "entity_2_type": "pm0104308", "entity_2_type_id": 139}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s0_HPRD50.d39.s0.p0", "text": "A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro", "text_with_entity_marker": "A prominent isolate, designated [E1]SRcyp[/E1]/[E2]CASP10[/E2], specifically interacts with the CTD not only in vivo but also in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRcyp", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "pm0120029", "entity_1_type_id": 144, "entity_2": "CASP10", "entity_2_idx": [[38, 44]], "entity_2_idx_in_text_with_entity_marker": [51, 57], "entity_2_type": "pm0122990", "entity_2_type_id": 145}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s0_HPRD50.d39.s0.p1", "text": "A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro", "text_with_entity_marker": "A prominent isolate, designated [E1]SRcyp[/E1]/CASP10, specifically interacts with the [E2]CTD[/E2] not only in vivo but also in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SRcyp", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "pm0120029", "entity_1_type_id": 144, "entity_2": "CTD", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0113359", "entity_2_type_id": 146}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s0_HPRD50.d39.s0.p2", "text": "A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro", "text_with_entity_marker": "A prominent isolate, designated SRcyp/[E1]CASP10[/E1], specifically interacts with the [E2]CTD[/E2] not only in vivo but also in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CASP10", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "pm0122990", "entity_1_type_id": 145, "entity_2": "CTD", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0113359", "entity_2_type_id": 146}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s1_HPRD50.d39.s1.p0", "text": "SRcyp is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing splicing factor SC35", "text_with_entity_marker": "[E1]SRcyp[/E1] is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing [E2]splicing factor SC35[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRcyp", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0120029", "entity_1_type_id": 144, "entity_2": "splicing factor SC35", "entity_2_idx": [[164, 184]], "entity_2_idx_in_text_with_entity_marker": [177, 197], "entity_2_type": "pm0120690", "entity_2_type_id": 147}], "directed": false, "reverse": false}
{"id": "HPRD50.d40.s0_HPRD50.d40.s0.p0", "text": "Transient expression of the full-length E2-2 without RSRS in U1240MG glioblastoma cells resulted in repression of FGF-1.B promoter activity", "text_with_entity_marker": "Transient expression of the full-length [E1]E2-2[/E1] without RSRS in U1240MG glioblastoma cells resulted in repression of [E2]FGF-1.B[/E2] promoter activity", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2-2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "pm0110165", "entity_1_type_id": 148, "entity_2": "FGF-1.B", "entity_2_idx": [[114, 121]], "entity_2_idx_in_text_with_entity_marker": [127, 134], "entity_2_type": "pm0124654-1.B", "entity_2_type_id": 149}], "directed": false, "reverse": false}
{"id": "HPRD50.d40.s1_HPRD50.d40.s1.p0", "text": "These results suggest that the relative abundance of the two splice variants of E2-2 in brain could be an important determinant for the expression of FGF-1", "text_with_entity_marker": "These results suggest that the relative abundance of the two splice variants of [E1]E2-2[/E1] in brain could be an important determinant for the expression of [E2]FGF-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2-2", "entity_1_idx": [[80, 84]], "entity_1_idx_in_text_with_entity_marker": [84, 88], "entity_1_type": "pm0110165", "entity_1_type_id": 148, "entity_2": "FGF-1", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "pm0124654", "entity_2_type_id": 16}], "directed": false, "reverse": false}
{"id": "HPRD50.d41.s0_HPRD50.d41.s0.p0", "text": "We report here that PLZF, and a structurally similar transcriptional repressor, BCL-6, can interact with a variety of corepressor proteins in addition to SMRT, including the mSin3A protein and (for PLZF) histone deacetylase-1", "text_with_entity_marker": "We report here that PLZF, and a structurally similar transcriptional repressor, [E1]BCL-6[/E1], can interact with a variety of corepressor proteins in addition to SMRT, including the mSin3A protein and (for PLZF) [E2]histone deacetylase-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BCL-6", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "pm0100563", "entity_1_type_id": 150, "entity_2": "histone deacetylase-1", "entity_2_idx": [[204, 225]], "entity_2_idx_in_text_with_entity_marker": [217, 238], "entity_2_type": "pm0119729", "entity_2_type_id": 108}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s0_HPRD50.d42.s0.p0", "text": "Herein, we show that a distinct IkappaB protein Bcl3 also interacts with RXR, as shown in the yeast two-hybrid tests and glutathione S-transferase pull-down assays", "text_with_entity_marker": "Herein, we show that a distinct IkappaB protein [E1]Bcl3[/E1] also interacts with RXR, as shown in the yeast two-hybrid tests and [E2]glutathione S-transferase[/E2] pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl3", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [52, 56], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "glutathione S-transferase", "entity_2_idx": [[121, 146]], "entity_2_idx_in_text_with_entity_marker": [134, 159], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s1_HPRD50.d42.s1.p0", "text": "In contrast to IkappaBbeta, Bcl3 did not interact with the AF2 domain of RXR", "text_with_entity_marker": "In contrast to [E1]IkappaBbeta[/E1], [E2]Bcl3[/E2] did not interact with the AF2 domain of RXR", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IkappaBbeta", "entity_1_idx": [[15, 26]], "entity_1_idx_in_text_with_entity_marker": [19, 30], "entity_1_type": "pm0122183", "entity_1_type_id": 152, "entity_2": "Bcl3", "entity_2_idx": [[28, 32]], "entity_2_idx_in_text_with_entity_marker": [41, 45], "entity_2_type": "pm0126712", "entity_2_type_id": 151}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p0", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "[E1]Bcl3[/E1] specifically interacted with the general transcription factors [E2]TFIIB[/E2], TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl3", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "TFIIB", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "pm0112772", "entity_2_type_id": 153}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p1", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "[E1]Bcl3[/E1] specifically interacted with the general transcription factors TFIIB, TBP, and [E2]TFIIA[/E2] but not with TFIIEalpha in the GST pull-down assays", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl3", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "TFIIA", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "pm0112153||pm0118250", "entity_2_type_id": 154}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p3", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "Bcl3 specifically interacted with the general transcription factors [E1]TFIIB[/E1], TBP, and [E2]TFIIA[/E2] but not with TFIIEalpha in the GST pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[68, 73]], "entity_1_idx_in_text_with_entity_marker": [72, 77], "entity_1_type": "pm0112772", "entity_1_type_id": 153, "entity_2": "TFIIA", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "pm0112153||pm0118250", "entity_2_type_id": 154}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p4", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "Bcl3 specifically interacted with the general transcription factors [E1]TFIIB[/E1], TBP, and TFIIA but not with TFIIEalpha in the [E2]GST[/E2] pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[68, 73]], "entity_1_idx_in_text_with_entity_marker": [72, 77], "entity_1_type": "pm0112772", "entity_1_type_id": 153, "entity_2": "GST", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p5", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and [E1]TFIIA[/E1] but not with TFIIEalpha in the [E2]GST[/E2] pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIA", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "pm0112153||pm0118250", "entity_1_type_id": 154, "entity_2": "GST", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s3_HPRD50.d42.s3.p0", "text": "TBP and TFIIA, however, were not able to interact with IkappaBbeta", "text_with_entity_marker": "TBP and [E1]TFIIA[/E1], however, were not able to interact with [E2]IkappaBbeta[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIA", "entity_1_idx": [[8, 13]], "entity_1_idx_in_text_with_entity_marker": [12, 17], "entity_1_type": "pm0112153||pm0118250", "entity_1_type_id": 154, "entity_2": "IkappaBbeta", "entity_2_idx": [[55, 66]], "entity_2_idx_in_text_with_entity_marker": [68, 79], "entity_2_type": "pm0122183", "entity_2_type_id": 152}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s4_HPRD50.d42.s4.p0", "text": "Accordingly, Bcl3 coactivated the 9-cis-RA-induced transactivations of RXR, in contrast to the inhibitory actions of IkappaBbeta", "text_with_entity_marker": "Accordingly, [E1]Bcl3[/E1] coactivated the 9-cis-RA-induced transactivations of RXR, in contrast to the inhibitory actions of [E2]IkappaBbeta[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl3", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "IkappaBbeta", "entity_2_idx": [[117, 128]], "entity_2_idx_in_text_with_entity_marker": [130, 141], "entity_2_type": "pm0122183", "entity_2_type_id": 152}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s5_HPRD50.d42.s5.p0", "text": "In addition, coexpression of SRC-1 but not p300 further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR", "text_with_entity_marker": "In addition, coexpression of [E1]SRC-1[/E1] but not [E2]p300[/E2] further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRC-1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0108797||pm0117490", "entity_1_type_id": 155, "entity_2": "p300", "entity_2_idx": [[43, 47]], "entity_2_idx_in_text_with_entity_marker": [56, 60], "entity_2_type": "pm0126787", "entity_2_type_id": 65}], "directed": false, "reverse": false}
